Development, Characterization, and Optimization of a Multi-Chamber, Single-Use Bioreactor by Amer, Momen
DEVELOPMENT, CHARACTERIZATION, AND 
OPTIMIZATION OF A MULTI-CHAMBER, SINGLE-
USE BIOREACTOR 
 
   By 
MOMEN AMER 
   Bachelor of Science in Pharmacy 
   Ain Shams University 
   Cairo, Egypt 
   2006 
 
   Master of Science in Biotechnology  
   The American University in Cairo 
   Cairo, Egypt 
   2014 
 
 
   Submitted to the Faculty of the 
   Graduate College of the 
   Oklahoma State University 
   in partial fulfillment of 
   the requirements for 
   the Degree of 
   DOCTOR OF PHILOSOPHY  
   May, 2019  
ii 
 
   DEVELOPMENT, CHARACTERIZATION, AND 




   Dissertation Approved: 
 
   Dr. Joshua D. Ramsey 
  Dissertation Adviser 
   Dr. Heather Gappa-Fahlenkamp 
 
   Dr. Ashlee N. Ford Versypt 
 
   Dr. James E. Smay 
  
iii 
Acknowledgements reflect the views of the author and are not endorsed by committee 




I would like to acknowledge everyone who helped me to do this work and turn 
my ideas into reality. First, I would like to thank my advisor, Dr. Josh Ramsey, for 
believing in my ideas and for his continuous support along the way. I would like to thank 
Dr. Fahlenkamp, Dr. Ford Versypt, and Dr. Smay for serving on my committee, and Dr. 
Feng for the great expertise he provided in the CFD part of this work.  
My sincere thanks go to Richard Gajan for all his valuable advice and his huge 
assistance in developing the business side of this work. I would like to thank Daniel Will 
and Cowboy Technologies team for financially supporting this work. I would also like to 
thank everyone at the Technology Development Center: Russell Hopper, Alex Valiaev, 
and Scott Davis who opened the door to a lot of great learning and funding opportunities 
that made this work come to reality. 
Finally, I would like to thank my wife and my lab mate, Yasmine Gabal, for all 
her support and sacrifices. I am especially thankful to my parents for their endless 
support, encouragement, and inspiration. Mom, I know you would have been so proud.
iv 
 
Name: MOMEN AMER   
 
Date of Degree: MAY, 2019 
  
Title of Study: DEVELOPMENT, CHARACTERIZATION, AND OPTIMIZATION OF 
A MULTI-CHAMBER, SINGLE-USE BIOREACTOR 
 
Major Field: CHEMICAL ENGINEERING 
 
Abstract: Stirred-tank single-use bioreactors have proven their capability to successfully 
replace their stainless-steel counterparts in the biopharmaceutical industry. To date, 
however, only a five-fold volume expansion is achievable in a single-use stirred tank 
bioreactor, which in turn necessitates intermediate equipment to scale-up the culture to 
production volume. This work introduces a novel multi-chamber single-use bioreactor 
design that can help users save costs of purchase and qualification of equipment, reduce 
factory footprint, and reduce the risk of contamination. A bioreactor prototype is 
presented in this work that is made of two chambers of different volumes, interconnected 
as a single, closed system. The design and construction of the prototype is described in 
detail, and engineering characterization results are reported for both chambers and 
compared with published data for commercially available bioreactors. The results help 
identify some areas of potential improvements in the bioreactor design. Optimization of a 
bioreactor design can be an especially challenging process and can lead to an exceedingly 
large number of configurations and necessary experiments. Therefore, a computational 
fluid dynamics model is used in this work to model the multiphase flow in the 50 L 
chamber of the multi-chamber bioreactor prototype. The model results are validated with 
oxygen mass transfer coefficient (kLa) measurements within the prototype. The validated 
model is projected to predict the effect of using different sparger types and sizes and the 
effect of varying the impeller diameter on kLa. The simulations show that ring spargers 
result in a superior kLa compared to pipe spargers, with an optimum sparger-to-impeller 
diameter ratio of 0.8. Also, larger impellers are shown to improve kLa. A correlation of 
kLa is presented as a function of both the reactor geometry and operating conditions. The 
resulting correlation can be used to predict kLa in a bioreactor and to optimize its design 
and operating parameters. Finally, a full commercialization plan for the multi-chamber 
bioreactor is presented. The plan proves that the proposed design not only offers a 
solution to a variety of industry problems but also presents an attractive investment 
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1.1 Upstream Processing in Biopharmaceutical Manufacturing 
The first critical step in biopharmaceutical manufacturing from mammalian cells is the 
upstream processing. The process is based on seed-train expansion, where the cell culture volume 
is scaled from a few milliliters up to hundreds or thousands of liters at the production scale. The 
scale-up process is critical because the quality of the inoculum in the early cultivation stages 
often determines the quality of the entire production campaign. Therefore, keeping the cells in a 
good state throughout the whole seed-train process is essential [1, 2]. 
A cell culture seed-train is time consuming and generates significant corresponding costs. 
A typical seed-train from a 2 mL scale until inoculation of a 3,000-10,000 L production scale 
bioreactor lasts in the range of 20-30 days. Deviations from standard growth rates or 
contamination incidents are common, and if they happen, they will further increase the seed-train 
time span. Typical seed-train protocols start by thawing a 1-2 mL cryopreserved cell suspension 
vial, and then the cells are transferred and cultivated in T-flasks. T-flasks are routinely incubated 
in CO2 controlled incubators, where cells can grow and multiply. Based on the cell density, which 
is the number of viable cells per milliliter of cell suspension, the cells undergo successive sub-
cultivation (i.e. passaging) into larger vessels. While a T-flask can handle 
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tens of milliliters of culture volume, roller bottles or shake flasks can handle hundreds of milliliters 
and bioreactors are subsequently used to handle larger scales up to thousands of liters. On reaching a 
sufficient viable cell density, the cells are transferred to the production scale bioreactor. In all seed-
train vessels, the cell culture typically lasts for 2-3 days before it is transferred to the larger vessel. In 
the production scale bioreactor, however, cells are cultivated for a longer period, usually more than 
seven days, where the cell growth, productivity, and metabolic activity are monitored. At the end of 
the production run, cells are harvested by being separated from the culture media. The culture media 
then undergoes a whole sequence of events in the downstream processing in order to purify the 
biopharmaceutical protein of interest. 
 
Figure 1.1. Seed-train process of a cell culture production run starting from a few milliliters of frozen cell 
culture up to thousands of liters. 
The seed-train process, as described, is both time and cost intensive. A lot of manual 
operations and handling as well as the use of many culture vessels are required [3]. Excessive 
operator handling increases the risk of microbial contamination, especially during the transfer of the 
culture from one vessel to another. The use of multiple pieces of equipment also creates its own 
challenges. In addition to the high cost associated with the purchase, qualification, and maintenance 
of multiple pieces of equipment, they also occupy much of the production facility floor space and 
limit the production capacity.  
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Efforts to offset the limitations of seed-train procedures include high density and/or large 
volume cell banking, using perfusion systems to seed the production bioreactor, and increasing 
bioreactor turndown ratio. These approaches aim to streamline the seed-train by reducing the process 
timeline, factory foot print, and operator’s interference.  
1.1.1 High Density and/or Large Volume Cell Banking 
Generating enough cell mass from a 1-2 mL cryo-vial to initiate the production bioreactor is 
time consuming. The process can take weeks and is dependent on scale, cell line characteristics, and 
the process parameters [2]. Previous efforts have shown that high-density cell banking can be an 
effective means to reduce the number of steps required and improve operational success in seed-train 
process. Tao et al. [4] reported using a perfusion system to generate high density cell banks for 
Chinese hamster ovary (CHO) cells. Cell banks were generated at 90-100 million cells/mL and were 
used to directly inoculate a 20 L Wave bag. This approach eliminated multiple intermediate shake-
flask expansion steps and reduced the cell culture process time by up to 9 days at 2,000 L 
manufacturing scale. In other studies, cryo-bags were used to freeze 50-100 mL of CHO and baby 
hamster kidney (BHK) cells at a density of 20-40 million cells/mL [2, 5]. Cells were thawed and 
directly transferred to an inoculation bioreactor at a volume of 2 L. The culture volume in the 
inoculation bioreactor was stepwise increased to its final working volume and the cells were used to 
directly inoculate the production bioreactor after a sufficient cell density was reached. This strategy 
was claimed to reduce seed-train expansion duration by 60–70%. 
1.1.2 Using Perfusion Systems to Seed the Production Bioreactor 
A perfusion cell culture system involves a continuous supply of fresh media into the 
bioreactor while the waste byproducts are constantly removed. The advantage of perfusion system is 
that a much higher cell density can be attained in a relatively small volume bioreactor [6]. Thus, a 
higher volumetric productivity than conventional batch or fed batch conditions can be achieved. 
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Perfusion systems are therefore often considered as production bioreactors rather than as elements of 
seed-train process [7].  
Some studies, however, proposed the use of a perfusion n – 1 stage bioreactor (the seed-train 
bioreactor stage immediately prior to the production bioreactor stage) to reduce the seed expansion 
time by reducing either the number of expansion steps or the growth phase duration in the production 
bioreactor. Kloth et al. [8] proposed the use of a 5 L perfusion bioreactor to inoculate multiple 35 L 
production scale bioreactors. After inoculation, the perfusion seed bioreactor was replenished with 
fresh nutrient medium and continued to operate until other production bioreactors required 
inoculation. Using this method, the seed-train duration was minimized by inoculating multiple 
bioreactors in a short period. Pohlscheidt et al. [9] achieved high cell densities up to 15.6 million 
cells/mL in a 3,000 L n – 1 perfusion bioreactor, which was then used to inoculate a 13,500 L fed 
batch production bioreactor. The inoculation cell densities from the perfusion n – 1 were four‐fold 
and an eight‐fold higher than those used in a conventional process where the production bioreactor 
was inoculated from a batch n – 1 bioreactor. This process provided a 3 days reduction in the 
production process and an estimated increase in the facility utilization by 12% - 19%. Padawer et al. 
[10] also proposed using a perfusion n – 1 bioreactor to inoculate the production fed batch bioreactor 
at a 25-fold higher cell density. A production time reduction from 14 to 8 days was achieved using 
this approach. 
Wright et al. [7] described a seed-train process that combined the use of high density cell 
banking and a perfusion bioreactor at the n – 1 stage. Compared to a conventional process, the use of 
high cell density cell banking eliminated two intermediate expansion stages in the seed-train process, 
while the use of a 50 L n – 1 perfusion system allowed for a 10-fold increase in the seeding density at 
the 500 L production bioreactor. The higher seeding density reduced the growth phase duration inside 
the production bioreactor by 5 days. 
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1.1.3 Increasing the Bioreactor Turndown Ratio 
The turndown ratio for a bioreactor is the ratio between its maximum and minimum operating 
volumes. For most cell cultures, a 1:5 ratio is used for scaling up the culture volume in each 
passaging step [11]. A bioreactor that is capable of operating at 20% or less of its maximum capacity 
can support two expansion stages of the seed-train process. The bioreactor can be initially seeded at 
20% of its working volume, and when the cell culture reaches a sufficient cell density, fresh nutrient 
medium is added to scale the volume up to the full capacity of the bioreactor. Operating bioreactors at 
a 20% or less of their maximum working volume, however, comes with a challenge. Bioreactors are 
typically designed with top overlay and bottom spargers. At low culture volumes (i.e. 20% of the total 
bioreactor volume), the headspace volume is large (i.e. 80% of the total bioreactor volume) and is 
filled with carbon dioxide and other metabolic gases. The top sparger is not efficient to flush such a 
large headspace volume. Thus, the heavier CO2 forms a blanket at the surface of the culture and 
causes a higher level of dissolved CO2 in the culture and a lower oxygen transfer, which negatively 
affects the cell culture performance [11]. 
In order to tackle this problem, Thermo Fisher Scientific achieved good cell culture 
performance in their HyPerforma S.U.B. with a 5:1 turndown ratio by introducing an extra crossflow 
sparger in their bag design. When the bioreactor operated at 20% working volume, the crossflow 
sparger introduced gas just above the liquid height and produced more efficient oxygen transfer and 
CO2 removal from the culture. Best results were achieved when the crossflow sparger was positioned 
within 12-15 inches above the liquid surface. The efficiency of CO2 stripping declined when the 
crossflow sparger was positioned at higher locations, even when the gassing flow rate was increased 
by fivefold.  
A seed-train process based on high turndown bioreactors (i.e. 5:1) is expected to require 
fewer intermediate bioreactors than a process based on 2:1 turndown bioreactors. For a 2,000 L 
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production process, the elimination of one intermediate unit is estimated to reduce the operator 
intervention by 15-25%. The risk of operator error is reduced by decreasing the number of setups and 
aseptic transfers and by spacing out peak operational labor loads, which results in reduced risk of 
culture contamination. The benefits of using fewer pieces of equipment in the seed-train process also 
include increased facility space and reduced fixed costs associated with the purchase and qualification 
of equipment [12].  
1.2 Significance of the Research 
The overall aim of this work is to develop one smart solution to various problems in the 
upstream processing of mammalian cell culture in biopharmaceutical industry. A multi-chamber 
single-use bioreactor has an innovative, patent-pending design. In addition to all the general benefits 
of single-use bioreactors discussed in Chapter 2, the new design also offers some extra benefits to the 
current industry practices. These benefits include the reduction of factory footprint, capital costs, 
operating costs, and risk of microbial contamination.  
Chapter 3 of this work presents the methods of developing an early 50 L prototype of the 
multi-chamber single-use bioreactor. The chapter also provides a comparative engineering 
characterization between the prototype and other commercially available single-use bioreactors of 
similar volumes. A more automation friendly method to produce the second generation 200 L 
prototype is also presented in Chapter 3.  
In Chapter 4, a multiphase CFD model with population balance equations is used to model 
gas-liquid mixing and gas bubble distribution in the larger chamber of the early prototype. The model 
is used to predict the effect of using ring or pipe spargers of different sizes and the effect of varying 
the impeller diameter on the oxygen mass transfer coefficient (kLa). Design of experiment methods 




Finally, in Chapter 5, a full commercialization plan for the multi-chamber single-use 
bioreactor is presented with 5-year financial projections. The commercialization plan is based on 
founding a limited liability company, referred to as Multivate LLC. Foreseeing the design patent is 
granted, the plan assumes Multivate licensing the intellectual property rights from Oklahoma State 
University. The financial projections are based on Multivate’s success to secure $600,000 investment. 
Collectively, the work integrates engineering, computational, biological, and business concepts to 
develop a novel solution to current problems in biopharmaceutical industry. The work shows that the 







SINGLE-USE BIOREACTORS AND APPLICATION OF COMPUTATIONAL FLUID 
DYNAMICS IN BIOPHARMACEUTICAL INDUSTRY 
 
2.1 Single-Use Bioreactors in Biopharmaceutical Industry 
In addition to the challenges associated with the risky and time-consuming seed-train 
process, other challenges have developed in the past few years facing the biopharmaceutical 
industry. The rising biosimilar (i.e. biopharmaceutical generics) competition and the increased 
quality standards required by regulatory agents put an increasing pressure on the 
biopharmaceutical manufacturers to drive toward developing more efficient processes at lower 
costs [13]. Over the past two decades, single-use technologies have shown success in developing 
efficient, low cost, and flexible manufacturing bioprocesses [14]. 
2.1.1 Advantages of Single-Use Technology 
Single-use bioreactors are pre-sterilized, ready to use vessels that are used once and then 
disposed of. The first single-use bioreactor was introduced to market in 1996 [15]. Since then, 
single-use bioreactors have been hugely successful in replacing their stainless-steel counterparts   




Biopharmaceutical manufacturing is tightly controlled by current good manufacturing 
practice (cGMP) guidelines. In cGMP manufacturing practices, cleaning of all equipment that comes 
into contact with the product is a crucial procedure that needs to take place in between runs [17]. This 
cleaning process is laborious, time consuming, and requires a complete shutdown of the production 
line. The cleaning procedures also need an extensive validation and documentation [18]. Using 
single-use bioreactors eliminates the need of the cleaning process between runs and thus reduces the 
validation time and shorten time to market [19]. 
Single-use bioreactors provide a huge advantage in reducing the production downtime. The 
time required to prepare a single-use bioreactor for the next batch of the same product is estimated to 
be 2 hours compared to 6-10 hours for a changeover in a stainless-steel bioreactor. For a full product 
changeover, the time saving reward of using a single-use bioreactor is more prominent. While a full 
product changeover in a stainless-steel based process can take up to three weeks, it would not take 
more than 48 hours with a full disposable manufacturing process [20]. 
While clean-in-place (CIP) is required for stainless-steel bioreactors to eliminate the risk of 
cross contamination between multiple products, steam-in-place (SIP) is also required to sterilize the 
stainless-steel bioreactor before each use to reduce the risk of microbial contamination. Single-use 
based processes eliminate the need of SIP, which brings an additional environmental benefit in 
lowering the consumption of highly pure water and heat required to clean and sterilize the stainless-
steel systems. The environmental benefit of the reduced energy demand has been reviewed in some 
studies and was demonstrated to overweigh the negative impact of increased solid waste generated 
from single-use systems [21, 22].  
Economic benefits of single-use equipment also include reduction of initial capital burden 
and time required to get a facility up and running. The total capital costs for a single-use based facility 
was reduced by 54% compared to a stainless-steel based facility, as estimated in a study published in 
10 
 
2009 [23]. Operating costs are also reduced by adopting single-use equipment. In 2013, estimates 
indicated that compared to stainless-steel facilities, single-use operated facilities had annual 
production rates that were 27% greater and production costs that were 23% lower on a gram of mAb 
basis [24].  
2.1.2 Current Challenges and Limitations for Single-Use Technology 
2.1.2.1 Lack of Universal Regulatory Standards 
A current challenge that faces the single-use technology is the lack of standardization of 
components. The manufacturers of single-use technology products need to conduct extensive 
physical, functional, chemical, biological, and sterilization validation evaluations on their products 
and to ensure their compliance with multiple qualification specifications [25]. The lack of standard 
materials of construction, testing, and certifications provided by suppliers limits the ability of the end-
users to easily inter-change or inter-connect different process components or to have more flexibility 
to choose between different suppliers and components [26]. As a part of the process validation, the 
end-users need to perform risk assessment studies to demonstrate that their selected supplier materials 
are compatible with their products and processing conditions [27, 28]. 
2.1.2.2 Leachables and Extractables 
The use of single-use technologies raises the concern of organic compounds leaching from 
the plastic surfaces into the process fluid. Leachables refer to chemicals that migrate into the actual 
drug product from the product contact surface under normal use conditions, whereas extractables are 
the chemicals extracted from the product surface materials under extreme conditions of using specific 
solvents and high temperatures. As a part of process validation, determination of extractables and 
leachables levels for single-use systems must be done. Studies showed that leachables from 
commercially available bags can adversely affect cell growth [29]. Leachables also have the potential 
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to bind to media components, especially the lipid components needed to cultivate NS0 cholesterol 
dependent cells [30, 31].  
Suppliers of single-use systems are required to provide extractable profiles under extreme 
solvent and temperature conditions. The provided data should include both identification and 
quantification of extractables [32, 33]. Leachables are usually a subset of extractables. Under normal 
conditions, leachables are expected to be released in very low levels, if any. A major progression is 
required to arrive at a common standard set of conditions and analytical techniques to quantify 
extractables in various single-use products from different suppliers [34]. 
2.1.2.3 Limited Scale 
Scalability is one challenge facing upstream single-use technology. Single-use bioreactors 
have been limited predominantly to 2,000 L or less for mammalian cell cultures. Leakage and 
integrity issues have been of big concern when considering the use of disposable bioreactors at large 
volumes. The plastic materials that are currently used to produce single-use bioreactor films are not 
capable of sustaining high pressures without compromising their integrity [26, 35]. This volume 
limitation of single-use bioreactor improved in late 2015, when ABEC, Inc. announced the industry’s 
largest single-use bioreactor so far with a working volume of 3,500 L. Although this is a noticeable 
increase, the ABEC bioreactor is not yet widely used, and compared to a typical 20,000 L stainless-
steel bioreactor, the ABEC bioreactor is still quite limited.  
Despite the scale limitation, the 2,000 L maximum scale of single-use bioreactors is 
becoming more adopted in industry because of many reasons. Some of these reasons are the increased 
product titers as a result of improvements in cell line development and cell culture processes, 
increased number of biologics targeting orphan diseases and smaller patient population, and the rapid 
market growth of biosimilars [35].  
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2.1.2.4 Environmental Impact 
At first glance, single-use products might seem less sustainable than their reusable 
counterparts. Single-use systems, however, were shown to have less environmental impact than 
stainless-steel components. The higher environmental impact of using stainless-steel systems is 
primarily due to the extensive use of highly purified water and heat required for cleaning and 
sterilization of such systems.  
One study that compared the use of disposables to the use of stainless-steel components in a  
3 × 2,000 L scale facility demonstrated that the most significant savings were derived from reductions 
in water usage. The study estimated 87% reduction in water usage in the single-use based facility, 
38% space reduction, and 30% reduction in energy to operate the facility compared to the stainless-
steel based facility. In total, 25.5% reduction in carbon footprint was estimated when using the 
disposable systems [36]. GE Healthcare Life Sciences performed a lifecycle assessment study that 
showed that the end-of-life disposal of single-use components has negligible impact when compared 
to other factors such as energy and water use in stainless-steel based production processes [37]. 
Waste disposal of single-use systems, however, is still a complex issue that needs to be 
addressed. Options for disposal include landfill, waste to energy incineration (WtE), and recycling. 
One challenge that comes with disposing single-use components of bioprocessing is that they are 
classified as bio-hazardous materials. The end-user needs to autoclave the waste material before 
sending them to the waste management vendors to be buried in a landfill. Another option is to send 
the waste to WtE facilities where the plastic is burned to release electric or heat energy. However, the 
manufacturing facility might not have a WtE facility near its site. Also, not all WtE facilities accept 
bio-hazardous materials. Recycling also comes with a significant challenge where single-use systems 
are usually made up of different types of plastic materials that are difficult to separate [21]. 
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2.1.2.5 Application in Microbial Cultures 
Single-use bioreactors have not been widely used in microbial cultures. Microbial cultures have 
very high metabolic rates and oxygen demands, and they typically run under high pressure and high 
gas flow rate. For a plastic-made single-use bioreactor, it is a big challenge to provide the needed 
power required for adequate mixing and oxygen mass transfer. The low heat transfer rate of the 
plastic material of the bags also generates excessive heat and makes it challenging to maintain the 
temperature of the culture inside the bioreactor. For the above-mentioned reasons, the use of single-
use bioreactors in microbial cultures is not common and is limited to a maximum of only 200-500 L 
[35, 38, 39]. 
2.1.2.6 Sensor and Monitoring Technology 
The concept of process analytical technologies (PAT) was introduced by the FDA to improve 
process monitoring and to allow online control rather than testing the final product specifications at 
the end of the process [40, 41]. PAT is associated with the quality by design (QbD) concept, which 
aims to minimize production error by building quality within the process [42]. A big focus, therefore, 
has been placed to developing robust single-use sensor technologies. The most commonly used 
sensors are fluorescent-based pH, dissolved oxygen, and carbon dioxide sensors. Recent technologies 
include sensors for viable cell mass, glucose, and lactate concentrations [35]. 
Table 2.1. Summary of advantages and disadvantages of single-use technology in biopharmaceutical 
industry. 
Advantages Disadvantages 
Reduced risk of cross contamination between 
different products 
Limited scale, especially in microbial 
fermentation 
Reduced capital costs Waste disposal 
Reduced need for cleaning validation Lack of universal standards 
Eliminated need for CIP and SIP Leachables and extractables 
Reduced turn down time and accelerated time to 
market 
Limited number of vendors 
14 
 
2.2 Computational Fluid Dynamics in Bioreactor Design 
Computational fluid dynamics (CFD) is a computer aided technique that uses numerical 
methods and algorithms to describe fluid flow patterns. While CFD is a powerful tool to study and 
improve existing operating systems, CFD can also be used in the design of new systems to implement 
QbD concepts and shorten the product development cycle. Application of CFD in modeling 
pharmaceutical processes has gained a big interest in the past few decades [43-45], specially to model 
the fluid flow in bioreactors. 
2.2.1 Modelling of Rotating Systems in Agitated Tanks 
Many scientific papers have used CFD to model fluid flow and turbulence inside agitated 
systems [46-50]. CFD models have been proven to predict with sufficient accuracy the mean flow-
field and the power number in various agitated bioreactor systems equipped with different types of 
impellers [51-56]. 
Efficient mixing is crucial in cell culture and fermentation processes to ensure even 
distribution of nutrients, oxygen, and pH. CFD has been frequently employed to study the mixing 
performance in stirred-tank reactors [57-61], and how mixing is affected by the reactor hardware 
configuration [52]. The multiple reference frame and the sliding mesh models are often used to model 
rotating motion in agitated tanks.  
2.2.1.1 Multiple Reference Frame Model  
In the multiple reference frame model, two distinct fluid domains are created. A rotating 
reference frame is defined at the impeller region and is set to rotate at a velocity corresponding to the 
impeller tip speed. The other domain is set as a stationary reference frame in the outer region. At the 
interfaces between cell zones, a local reference frame transformation is performed to enable flow 
variables in one zone to be used to calculate fluxes at the boundary of the adjacent zone. 
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2.2.1.2 Sliding Mesh Model 
In the sliding mesh technique, two or more cell zones are used. The interface zones of 
adjacent cell zones are associated with one another to form a "mesh interface''. During the calculation, 
the cell zones slide relative to one another along the mesh interface in discrete time steps and perform 
time-dependent calculations using implicit or explicit interpolation of data at successive time steps. 
The sliding mesh model provides a time-accurate rather than a time-averaged solution. The model is 
the most accurate method for simulating flows in multiple moving reference frames, but also the most 
computationally demanding. 
2.2.2 Multiphase Flow Modelling 
Many studies used CFD to model multiphase flow including gas phase, particle tracking, or 
reaction processes in stirred-tank reactors [52, 62-67]. In cell culture and aerobic fermentation 
systems, the rate of oxygen transfer to the cells is critical. The rate of oxygen transfer is dependent on 
the bubble size distribution, because bubble sizes dictate the available surface area for gas-liquid mass 
transfer [68]. Modelling multi-phase flow in aerated tanks, requires taking bubble breakage and 
coalescence into account. Population balance models, therefore, have been used to model the 
evolution of gas bubbles in bioreactors [69-71]. However, the mechanisms responsible for bubble 
breakage and coalescence are not yet fully understood and need further exploration [72].  
The CFD models can generate high-resolution localized predictions regarding some 
parameters that are hard or even impossible to measure in situ, such as the shear stress, power 
consumption, Kolmogrov eddy length scale distribution, and turbulence characteristics including 
Reynolds stress, kinetic energy, and energy dissipation rate [73-75]. 
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For multiphase flow, two computational approaches for modeling the interaction between 
phases have been widely used: the Euler-Lagrange approach [56, 76-78] and the Euler-Euler 
approach [56, 79-82].  
2.2.2.1 Euler-Lagrange Approach 
In the Euler-Lagrange approach, the primary phase is treated as a continuum by solving the 
time-averaged Navier-Stokes equations. In the secondary dispersed phase, the motion of large number 
of individual particles is tracked as the particles move through fluid. The Euler-Lagrange model is 
typically used when the secondary dispersed phase occupies a low volume fraction. The particle 
trajectories are computed individually at specified intervals during the fluid phase calculation [83]. 
2.2.2.2 Euler-Euler Approach 
In the Euler-Euler approach, both dispersed and continuous phases are treated as inter-
penetrating continua. The concept of volume fraction is introduced because the volume of one phase 
cannot be occupied by another phase. These volume fractions are assumed to be continuous functions 
of space and time, and their sum is equal to one. The Euler-Euler model is computationally more 
economical than the Euler-Lagrange model, and it can handle both dilute and dense flows [83]. 
2.2.3 CFD in Modelling Single-Use Bioreactors 
The suitability of CFD models for engineering characterization of single-use bioreactors has 
been demonstrated. Many case studies have been reviewed by Loffelholz et al. [84], as well as some 
other recent studies [85, 86]. These studies involved stirred-tank and wave-mixed bioreactors, as well 
as other bioreactor designs with uncommon mixing mechanisms like the oscillating disk with conical 
orifice in the Vibromix system and the air wheel in the PBS Biotech bioreactor. The case study of the 
PBS bioreactor was unique in the sense that the CFD simulations were used to develop the market 
ready bioreactor based on only a prototype, which relates to one scope of this work regarding the 
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multi-chamber bioreactor development. Applying CFD in the bioreactor development process led to a 
significant reduction in time and costs [84]. CFD has been also used to optimize cultivation and scale-
up conditions in bioreactors by predicting the critical shear stress and hence proposing optimum 






DEVELOPMENT AND CHARACTERIZATION OF THE MULTI-CHAMBER SINGLE-USE 
BIOREACTOR - A PROOF OF CONCEPT PROTOTYPE 
 
This Chapter is published in Biochemical Engineering Journal, 15 February 2018, Volume 130, 
pages 113-120 [115]. 
3.1 Introduction 
For quite some time, the gold standard for upstream processing in the biopharmaceutical 
industry has been reusable stainless-steel bioreactors. however, since the first WAVE bioreactor 
system was introduced in the late 1990s [15], single-use technology has garnered extensive 
interest and been a tremendous success in the field [16]. Drawbacks associated with the use of 
stainless-steel bioreactors have helped lead to the quick adoption of single-use technology. The 
need for continual re-sterilization, reduction of the overall production time due to required 
cleaning time between batches, and increased risk of cross contamination between different cell 
lines or proteins produced in the same bioreactor are commonly acknowledged as some of the 
biggest drawbacks [89]. In contrast, processes based on single-use technology offer many 
advantages. Disposable systems eliminate the need for cleaning-in-place, sterilization-in-place, 
and cleaning validation. They also reduce the risks of cross contamination and decrease 
production turnaround times [90]. Further, reduction in validation time shortens time to  
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market [19], which is undoubtedly a tremendous value given the extensive development and 
increased demand of recombinant protein therapeutics. Moreover, compared to a stainless-steel 
facility, a single-use technology operated facility is estimated to complete 27% more production 
batchesper year to save about 23% of the cost for every gram of mAb produced. The same study 
also suggests that a modular facility incorporating single-use equipment for manufacturing would 
save over a year in design and construction compared to a conventional facility, and hence, would 
generate a faster return on investment [24].  
There are still key challenges facing single-use technology developers and end-users. One 
challenge is the limited bioreactor volume, where single-use bioreactors have been limited 
predominantly to 2,000 L or less for mammalian and insect cell cultures. This limitation 
improved slightly in late 2015, when ABEC, Inc. announced the industry’s largest single-use 
bioreactor so far with a working volume of 3,500 L. Although this is a noticeable increase, the 
ABEC bioreactor is not yet widely used, and compared to a typical 20,000 L stainless-steel 
bioreactor, the ABEC bioreactor is still quite limited. For microbial fermentations, disposable 
systems still pose significant engineering challenges. These challenges are attributed to the fact 
that in aerobic microbial fermentations, oxygen demand and the rate of heat evolution are 25-70 
times higher than in mammalian and insect cell cultures. Thus, much faster transfer of oxygen 
and better removal of heat from the culture are required. These needs are mostly addressed within 
glass and stainless-steel bioreactors but are not yet fully met within large volume bioreactors built 
from disposable plastics [38, 39]. Despite regulatory guidelines, leachables and extractables from 
disposable plastics still impose a risk, especially with existing studies showing that leachables 
from commercially available bags adversely affect cell growth [29]. 
A single-use bioreactor system typically consists of a fixed support structure and a 
control unit. The bioreactor is a disposable bag that is inserted in the support structure and 
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connected to the control unit which has the process control software installed. The bag is used for 
only one time and is then disconnected and disposed of when the batch is complete.  
A traditional single-use bag is designed as a single compartment bag with a typical 
turndown ratio (i.e., the ratio of the maximum and minimum capacity of the bag) in the range of 
2:1 to 5:1. Although the wave-rocking bioreactor Cell-tainer® is currently available in the market 
with the capability of expanding the cell culture volume by approximately 100-fold in the same 
bag (i.e., turndown ratio of ~100:1) [91], the unusual mixing principle and restricted scalability of 
a wave-rocking bioreactor often limits its use to low volume and simple applications such as 
seed-train expansion. For stirred tank reactors, the turndown ratio is still 5:1 at maximum. This 
volume limitation for cell cultivation inside a single, disposable bag necessitates the use of 
multiple bags with different working volumes throughout the seed-train process, which is the 
process of a stepwise scale-up of cell culture until inoculating the production scale bioreactor. 
Each of these intermediate bags typically requires its own control unit and support structure. In 
addition to the high cost, the large amount of equipment requires significant production floor 
space, as well as a regular qualification and documentation upon operation. Moreover, a stepwise 
seed-train process requires connecting separate bags each time the cultivated cells and nutrient 
medium are transferred from the smaller to larger bag, a procedure that requires highly trained 
personnel working under aseptic conditions.  
Here, we introduce a novel design for a single-use, multi-chamber stirred tank bioreactor. 
The two-chamber bioreactor presented in this study is an early prototype demonstrating the 
concept of employing multiple chambers. The general design consists of an outer bag, or 
chamber, enclosing one or more additional smaller chambers. Together, all chambers require only 
a single control unit and supporting structure that fits the dimensions of the largest chamber. The 
current prototype has a small chamber with a minimum working volume of 1 L and a maximum 
working volume of 2.5 L. The large chamber has a working volume range from 12.5 to 50 L. 
21 
 
Thus, our prototype allows for a 50-fold expansion of the cell culture volume. Although this is 10 
times higher than the permissible range of any stirred tank single-use bioreactor, it is not the 
upper limit of the invention. While the two-chamber bioreactor prototype serves as a proof of 
concept, other volumes (e.g. a two-chambers bioreactor with a minimum working volume of 10 L 
and a maximum working volume of 1,000 L) and additional chambers (e.g. a three-chambers 
bioreactor with an operating volume range of 1 L-1,000 L) can be used.   
These unique design features enable a user to reduce production costs significantly, as the 
savings can be quite large when multiple seed-train intermediates are affected. This includes the 
costs associated with the purchase and qualification of the equipment, as well as the costs of 
current good manufacturing practice (cGMP) footprint. Freeing upstream production space can be 
of great value in industry, especially with the growing trend of providing fully equipped, modular 
flexible facilities, like the KUBio system from GE Healthcare and FlexMoSysTM from Sartorius 
Stedim Biotech [92]. The freed space can be used either for introducing more production scale 
bioreactors and multiplying the production capacity, or to include both upstream and downstream 
processing in the same room. Moreover, all chambers in our design are inter-connected through a 
closed tubing system. This allows the cell culture transfer from one chamber to another to be 
done simply using a peristaltic pump without the need of opening the system. This completely 
closed system reduces the risk of contamination by eliminating the processes of connecting 
separate bags for the transfer of the cell culture during the seed-train process. 
In this study, we describe the construction of the two-chamber bioreactor in detail. We 
also evaluate the engineering aspects in both chambers. This includes mixing time (𝜃𝑚), power 
input per unit volume (P/V) and oxygen mass transfer coefficient (𝑘𝐿𝑎). Our results are compared 




 3.2 Materials and Methods 
3.2.1 Construction of the Prototype 
A Mobius® CellReady 3 L bioreactor from Millipore was used as the smaller chamber of 
the two-chamber bioreactor, with some modifications. The shaft of the original vessel was 
replaced by a longer shaft, penetrating through the vessel bottom. The long shaft still carried the 
3-blade marine impeller of the Mobius® vessel and ended with another larger 3-blade marine 
impeller to serve for mixing in the large chamber (Figure 3.1A). A Eurostar 100 Control stirrer, 
from IKA® Works, Inc. was connected to the shaft from the top of the small chamber head plate 
and was used to control agitation. Nice Ports with integrated dissolved oxygen (DO) and pH 
sensors, from PreSens-Precision Sensing GmbH (Germany), were welded to the wall of the small 
vessel for DO and pH measurements, with the ultimate aim of DO and pH process control. A dip 
tube was inserted from the head plate of the small vessel, to allow the fluid transfer across the two 
chambers via a peristaltic pump. The Mobius® 3 L bioreactor base was removed. The probes 
openings on the head plate were plugged, and all bottom tubing ends were blinded, except for the 
microsparger, which was connected to the gas sparging port on the top of the larger chamber. An 
early version of the prototype used a large 50 L chamber constructed from a flexible, 
polyethylene (PE)-ethylene vinyl alcohol (EVOH) 9101 barrier film from Renolit Corp. 
(California, USA). The film was heat welded using an impulse hand sealer to shape the 50 L 
flexible bag. At the top of the bag, a spout with an open top sleeve was made (Figure 3.1B). The 
bag constructed from this film was used in mixing time measurements because of the superior 
transparency of the film. A second version of the prototype was constructed by Flex Concepts, 
Inc. (Utah, USA), according to same specifications used for the first prototype. A double layered 




Figure 3.1. Assembly of the multi-chamber bioreactor prototype. (A) 3 L chamber, (B) 50 L chamber, 
(C) the two chambers connected, and (D) operating two chambers assembly. (1,2) pH and DO sensor ports, 
(3) clamp wrapping the 50 L bag around the 3 L chamber, (4, 5) ports for optical fibers insertion to connect 
with pH and DO sensor ports (1, 2) on the 3 L chamber through internal tubing, (6,7) pH and DO sensor 
ports, (8) sampling port, (9) thermocouple port, (10) optical fibers, (11) heating blanket inserted in the 
pocket formed by flipping and wrapping the 50 L chamber sleeve around the 3 L chamber. 
The smaller chamber was fitted inside the open top sleeve (Figure 3.1C) and secured by a 
clamp to maintain the inner space of the larger chamber isolated from the outer atmosphere. Nice 
Ports with integrated DO and pH sensors were welded onto the surface of the larger chamber, and 
a sampling port and thermocouple port were added. Another two ports were welded on the side of 
the bag and are connected to the sensor ports of the smaller chamber, internally via silicone tubes. 
These tubes act as channels to connect optical fibers between the control unit and the sensors of 
the small chamber, while maintaining the sterile conditions in both chambers. Other ports for 
sparger, overlay gassing, exhaust and fluid transfer were welded at the top of the bag. Silicone 
tubes and Y-shaped connectors were used to connect these ports with the head plate ports of the 
smaller vessel, and clamps were used to control the flow across one or both chambers. A bottom 
port for harvesting was also welded to the bag. Securing the smaller chamber in the top sleeve of 
the larger one, creates an outer pocket surrounding the small chamber (Figure 3.1D). This pocket 
A       B      C           D 
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was used to insert a silicone rubber heating blanket for temperature control of the fluid inside the 
small chamber. The heating blanket was wrapped around the small chamber and connected to a 
thermocouple and a digital temperature controller. A similar approach was used to control 
temperature of the large vessel, with a heating blanket wrapped around its bottom part. 
3.2.2 Engineering Characterization of the Multi-Chamber Single-Use Bioreactor 
3.2.2.1 Mixing Time 
Mixing time was determined in both chambers using the de-colorization method 
described by Kaiser et al. [93]. Different fluid volumes and agitation speeds were tested under 
unaerated conditions. For every liter of deionized water, 12 mL of starch solution were added, 
and the fluid was then colorized by the addition of 0.2 mL/L of Lugol’s iodine. Then, 0.2 mL/L of 
the tracer (1M sodium thiosulfate) was pipetted into the fluid, and time was taken immediately 
until the blue color disappeared completely. Each measurement was taken three times, by the 
same person to minimize inter-observer differences. 
For the small 3 L chamber, measurements were taken using 1.5 L and 2.5 L volumes, at a 
tip speed ranging from 0.2 to 1.0 m/s. For the large 50 L chamber, measurements were taken at 
the maximum working volume at tip speeds of 0.6, 1.2, and 1.8 m/s. For the smaller chamber, 
results were compared to the published data for the Mobius® CellReady 3 L bioreactor [93]. For 
the larger 50 L chamber, results were compared to published experimental data for the Mobius® 
CellReady 50 L bioreactor [94] and the BIOSTAT® STR 50 L bioreactor [19]. While for 
HyClone 50 L S.U.B., the following regression of both experimental and computational fluid 
dynamics (CFD) data reported by Löffelholz [95] for mixing time (𝜃𝑚) as a function of the power 
input per unit volume (P/V) was used to generate data points for comparison.  
𝜃𝑚 = 63.5(𝑃 𝑉)⁄
−0.44
      (Equation 3.1) 
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3.2.2.2 Power Input 
The Eurostar 100 Control stirrer was used to obtain real-time torque measurements in the 
large 50 L chamber. These torque measurements were used to calculate (𝑃 𝑉)⁄  at different 
agitation speeds and aeration rates. The impeller power number (𝑁𝑒) was calculated subsequently 
using  
          𝑁𝑒  =
𝑉(𝑃 𝑉⁄ ) 
𝜌 𝑛3 𝐷5
 (Equation 3.2) 
where 𝜌 is the density of water at room temperature, 𝑛 is the impeller speed, 𝐷 is the impeller 
diameter, and 𝑉 is the fluid volume. 
The final reported 𝑁𝑒 was the average of 10 different calculations at different agitation 
speeds and with Reynolds number (Re) >10,000, which implies a fully turbulent flow and a 
constant 𝑁𝑒.  
3.2.2.3 Oxygen Mass Transfer 
Oxygen mass transfer coefficient (𝑘𝐿𝑎) was determined by the gassing-out method. First, 
nitrogen gas was sparged into the fluid, and the DO reading was monitored until it reached 0%. 
Then, air was sparged into the liquid at specific aeration rates and agitation speeds. The DO 
reading was recorded at regular time intervals using the Fibox 4 fiber optic oxygen transmitter 
from PreSens- Precision Sensing GmbH (Germany), until the DO level reached saturation. All 
measurements were taken in a phosphate buffer saline solution for the 50 L chamber and a 0.5 M 
sodium sulfate solution for the 3 L chamber. Using the following formula, 𝑘𝐿𝑎 was obtained: 





) =  −𝑘𝐿𝑎 𝑡   (Equation 3.3) 
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In the small chamber, 𝑘𝐿𝑎 was calculated at tip speeds of 0.4, 0.6, and 1.0 m/s and at 
aeration rates of 0.05, 0.10, and 0.15 VVM (volume of air per volume of liquid per minute). For 
the large chamber, measurements were taken at tip speeds of 0.6, 1.2, and 1.8 m/s at the aeration 
rate of 0.1 VVM. Results were compared to published data for the following commercial 
bioreactors: Mobius® CellReady 3 L [93], BIOSTAT® STR 50 L [19], and HyClone 50 L S.U.B 
[96]. 
3.3 Results and Discussion 
3.3.1 Geometrical Dimensions 
In our first attempt to design and construct a multi-chamber single-use bioreactor, we aim 
to achieve acceptable and predictable results of the reactor engineering evaluation. Serving that 
purpose, in all stages of development, our goal is to maintain a standard design of both chambers. 
This includes, a standard geometry, constructing materials, mixing, heating, and sparging 
approaches. 
The general configuration is a 3 L chamber within a larger 50 L chamber as depicted in 
Figure 3.1. The inner chamber is a Mobius CellReady 3 L bioreactor, which has been well 
characterized both experimentally and in terms of CFD simulations [86, 93]. Only minor 
modifications were implemented to the vessel in order to serve as the smaller chamber in our 
bioreactor. The most dominant of which is the exclusion and replacement of conventional probes 
with optical sensors mounted on the vessel wall. It is worth mentioning here that conventional, 
top mounted probes for the small chamber would be applicable in the two-chamber design 
presented in this study. However, our design, with the optical sensors mounted to the vessel wall, 
and an internal tubing serving as a secure channel for the optical fiber to connect the sensor to the 
control unit, offers an ultimate solution for any inner chamber in a multi-chamber bioreactor. For 
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instance, in a three-chamber bioreactor, the top mounted probes may still work for the smallest 
chamber, but our design would be necessary for the middle one. 
The 50 L chamber is designed with a minimum working volume of 12.5 L and a 
maximum of 50 L. The chamber has a diameter of 38.0 cm and an overall height of 67.0 cm. The 
liquid height at the maximum working volume is 44.0 cm, thus, the aspect ratio of the fluid inside 
the chamber is 1.2, which lies within the 1-3 range recommended by Barradas et al. [97] for 
stirred tank reactors. The approach to mixing in the large 50 L chamber is identical to that in the 
smaller one. A top mounted, centered, 3-blade marine impeller is used. Both chambers are 
unbaffled. The ratio of the impeller diameter to the vessel diameter (D/T ratio) is 0.55 in the 3 L 
chamber and 0.59 in the 50 L chamber. A 3-cm long pipe sparger with 10 µm holes is mounted 
just below the impeller in the large chamber. While for the smaller chamber, the standard 
Mobius® CellReady bioreactor microsparger with 15-30 µm pore size is used.  
3.3.2 Mixing Time 
For the 3 L chamber, removal of the conventional probes was expected to have a negative 
impact on mixing behavior. Whereas the long probes immersed in the liquid would act, somehow, 
like baffles and improve radial mixing. However, our mixing time measurements showed very 
consistent results with the original Mobius® CellReady 3 L vessel, with less than 20% deviation 




Figure 3.2. Mixing times in the small 3 L chamber versus the Mobius® CellReady 3 L bioreactor at 
1.5 and 2.5 L working volumes and different tip speeds. 
The 50 L chamber has a mixing mechanism similar to the smaller chamber, with a 
centered, 3-blade marine impeller and no internal baffles within the vessel. The centered impeller 
and lack of internal baffles could potentially lead to formation of a vortex at high agitation speeds 
and subsequently poor mixing. The three commercially available 50 L bioreactors used in this 
study avoid the formation of a vortex and poor mixing through various approaches. The HyClone 
S.U.B is designed with an angled impeller shaft. The BIOSTAT® STR has two impellers on a 
single shaft with one impeller located above the other, and the Mobius® CellReady bag contains 
baffles. For the simplicity, however, our strategy to enhance mixing is based on selecting a high 
(D/T) ratio. Nienow [98] showed that for any type of agitator, a larger D/T ratio improves bulk 
mixing. Other studies quantified the relationship between D/T ratio and mixing time, reporting 
that mixing time is inversely proportional to the squared D/T ratio [99, 100]. The D/T ratio in our 
large chamber is 0.59 compared to 0.32, 0.34, 0.38 and for the Mobius® CellReady, Hyclone 
S.U.B, and BIOSTAT® STR, bioreactors, respectively. Based on the D/T ratios of the 
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commercially available bioreactors and the relationship between mixing time and D/T ratio 
mentioned above, there is at a minimum of a 2.4-fold enhancement in the mixing time of our 50 L 
chamber compared to the commercially available bioreactors. An additional design approach we 
use to overcome potentially poor mixing is reduction of the aspect ratio. The liquid height to 
diameter ratio (H/T) in our large chamber is 1.2, compared to 1.3, 1.5, and 1.6 for the BIOSTAT® 
STR, Hyclone S.U.B, and Mobius® CellReady bioreactors, respectively. Others have also 
reported in the literature [101] that mixing time is directly proportional to the aspect ratio raised 
to the 2.5 power. According to this relationship, a 22% improvement in mixing time is achieved 
with just the 0.1 difference in aspect ratio between our chamber and the BIOSTAT® STR.  
While conditions that favor formation of a vortex tend to lead to poor mixing, our results 
show that the D/T and H/T ratios can be varied to compensate for these effects. From Figure 3.3, 
it can be presumed that at higher agitation rates, where the negative effects of vortex formation 
are likely to be most apparent, both the increase in the D/T ratio and the reduction of the H/T ratio 
work together to partially compensate for the negative effects of a centered impeller and lack of 
internal baffles on mixing. At lower agitation rates, where the negative effects of vortex 
formation are likely to be substantially less, the improvements gained by varying the D/T and H/T 
ratios are not offset. Consequently, the mixing time of our chamber is similar to those of the 
commercially available bioreactors at high agitation rates and significantly better than two of the 
three commercially available bioreactors at low agitation rates.  
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Figure 3.3. Mixing time in the large 50 L chamber versus BIOSTAT® STR [19], Mobius CellReady 
[94], and Hyclone S.U.B. 50 L bioreactors at maximum working volume and different tip speeds. 
(Mixing times reported for the Hyclone S.U.B. 50 L were generated from a regression of 
experimental and CFD data acquired by Löffelholz [95])  
3.3.3 Power Input 
Maintaining a constant P/V is one of the most commonly used approaches for scaling 
bioreactors. The impeller power number (Ne) is a dimensionless number that is a characteristic of 
the impeller geometry and is essential to predicting P/V at any operating condition using Equation 
3.2. As shown in Table 3.1, our torque measurements at ten different fully turbulent conditions, 
give an average power number of 0.32 ±0.01. This result is in good agreement with the 0.3 power 






Table 3.1. Torque measurements and calculated Reynolds number (Re), power input per unit volume 
(P/V), and impeller power number (𝑵𝒆) in the 50 L chamber at different agitation speeds.  
RPM Re Torque (N.cm) P/V (W/m3) 𝑁𝑒  
90 58,834 0.07 13.19 0.31 
120 78,445 0.13 32.67 0.33 
150 98,056 0.19 59.69 0.30 
160 104,593 0.21 70.37 0.30 
170 111,131 0.25 89.01 0.31 
180 117,668 0.29 109.33 0.32 
190 124,205 0.33 131.32 0.33 
200 130,742 0.37 154.99 0.33 
210 137,279 0.41 180.33 0.33 
 
As shown in Figure 3.4, calculated P/V values for our 50 L chamber are lower than those 
of the commercially available bioreactors. This can be attributed to the considerably low power 
number of our impeller, 0.3, compared to the power numbers reported for Hyclone 50 L S.U.B. 
[95] and BIOSTAT® STR 50 L with two 3-blade segment impellers [19], 2.2 and 1.3, 
respectively. Thus, for our reactor to operate at the same P/V of these commercially available 
bioreactors, a higher tip speed is needed. It is generally proposed to keep the tip speed value 
within the range of 1 and 2 m/s for mammalian cell cultures [103], which in our case, corresponds 
to a P/V range of 10-80 W/m3. This covers a wide spectrum of the typical 1-50 W/m3 range 
suggested for mammalian cell culture [104], with an average of 10 W/m3 [105]. Collectively, 
these results show that prototype can provide good mixing behavior at a relatively low power, 
without fearing cell damage. 
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Figure 3.4. Calculated P/V at different impeller tip speeds in the large 50 L chamber, HyClone 50 L 
S.U.B., and BIOSTAT® STR 50 L with 2 × 3-blade segment impellers. 
3.3.4 Oxygen Mass Transfer 
For aerobic processes like mammalian cell culture, the oxygen transfer rate becomes 
critical. The DO level should always be kept above a critical limit to maintain cell growth which 
is achieved by sparging air or pure oxygen into the culture. The mass transfer rate of oxygen to 
the culture, which is dependent on the oxygen mass transfer coefficient 𝑘𝐿𝑎, should be higher 
than the rate at which growing cells take up oxygen [106]. The oxygen mass transfer coefficient 
depends on several factors, including, but not limited to, agitation rate, gassing rate, and sparger 
type, size, and position [107]. The most common cell cultures require 𝑘𝐿𝑎 values between 5 and 
10 hr-1 [19]. 
As shown in Figure 3.5, experimentally determined 𝑘𝐿𝑎 values for the small 3 L chamber 
are in good agreement with published data for the Mobius® CellReady bioreactor [93], with a 
maximum difference of 25%. For the large 50 L chamber, 𝑘𝐿𝑎 values are in even better 
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agreement with published results for the BIOSTAT® STR 50 L bioreactor (less than 15% 
deviation) but only for the model using a ring sparger with an 800 µm pore size.  
 
Figure 3.5. 𝒌𝑳𝒂 values in the 3 L chamber at different aeration rates and tip speeds, compared to the 
experimental results for Mobius® CellReady 3 L.  
Results for the prototype are significantly lower when compared to data for the 
BIOSTAT STR 50 L bioreactor model that uses a microsparger with 150 µm pore size (Figure 
3.6). Sparger pore size clearly impacts kLa by affecting the bubble size and the resulting surface 
area available for mass transfer. Smaller bubbles are produced from spargers with smaller pores, 
which generates greater surface area at the gas-liquid interface and subsequently a higher oxygen 
transfer rate [19]. While this explains the higher 𝑘𝐿𝑎 values for the BIOSTAT
® STR 50 L 
bioreactor with a 150 µm pore size sparger compared to the bioreactor with an 800 µm pore size 
sparger, it does not explain why the 50 L chamber with a 10 µm pore size sparger had lower 𝑘𝐿𝑎 




Figure 3.6. Calculated kLa values at 0.1 VVM aeration rate and different tip speeds in the large 50 L 
chamber and the BIOSTAT STR 50 L with the 800 µm pore size ring sparger and the 150 µm pore 
size microsparger.  
Rewatkar et al. [108] studied the effect of different sparger designs on the fractional gas 
hold-up, which is the ratio of gas phase volume to the total fluid volume inside the reactor. The 
ring sparger, which is used in the BIOSTAT® STR 50 L bioreactor, was shown to have a 
consistent 20-30% improvement in gas hold up at different agitation rates, and hence greater 𝑘𝐿𝑎 
values. Also, Yawalkar et al. [109] reviewed a number of studies that directly correlated 𝑘𝐿𝑎 to 
P/V. Yet another factor that affects 𝑘𝐿𝑎 is the aspect ratio (H/T). A higher H/T yields a longer 
residence time of gas bubble and a higher 𝑘𝐿𝑎 [110]. 
In order to understand the impact of these factors on our results, it is important to note 
that while our prototype 50 L chamber is constructed with a pipe sparger, the BIOSTAT® STR 
bioreactor has a ring sparger. The BIOSTAT® STR bioreactor also has a higher P/V at the same 
tip speed, and a higher H/T. All these factors can, to some extent, explain the enhanced oxygen 
mass transfer behavior of the BIOSTAT® STR reactor with the 150 µm pore sparger. While these 
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factors are probably compensated with the big difference in the sparger pore size between our 
reactor and the 800 µm sparger of the other BIOSTAT STR model. 
The 𝑘𝐿𝑎 determined at the tip speed 1.2 m/s in the prototype 50 L chamber is about 26% 
higher than the 8.3 hr-1 value reported at the same tip speed and aeration rate for the HyClone 
50 L S.U.B, where a similar pipe sparger is used [96]. This improvement can be attributed to the 
smaller sparger pore size in our reactor (10 µm versus 15-30 µm in the HyClone 50 L S.U.B) and 
also to the higher impeller diameter to vessel diameter (D/T) ratio [111]. 
3.4 Optimization of the Manufacturing Process for a Second-Generation Prototype 
A new method for fabricating a second-generation 2 L to 200 L, two-chamber prototype 
was conducted in collaboration with FlexConcepts, the same bag manufacturer that collaborated 
in fabricating the first-generation prototype. The new fabrication method allowed a fully 
automated manufacturing process of the prototype with two flexible chambers. A shaft carrying 
the impellers for both chambers was fabricated from FDA approved plastics (Appendices A.5 and 
A.6). The shaft was designed to pass through two polyethylene housing disks (Figure 3.7A). Each 
polyethylene housing is designed with an air/liquid tight seal and bearings for the rotating shaft to 
ensure aseptic conditions and to prevent culture leakage (Appendices A.3 and A.4). The two 
chambers of the prototype were fabricated as two separate flexible bags at FlexConcepts using 
their specialized machinery and the double layered plastic films (Appendices A.1 and A.2). The 
films were then welded to the polyethylene housings of the shaft. The upper surface of the lower 
housing was welded to the bottom of the smaller bag, while the bottom surface was welded to the 
top of the larger chamber to create the configuration of the two chambers one on top of the other 
(Figure 3.7B). The smaller chamber was then pushed downwards to create a sealed pocket to 





Figure 3.7. Sketch for the second-generation prototype fabrication parts and assembly. (A) a shaft 
carrying impellers for mixing both chambers going through polyethylene housings with air-tight seal and 
bearings, (B) two-flexible chambers welded to the polyethylene housings on the shaft, (C) the smaller 
chamber pushed downwards creating a sealed pocket. 
3.5 Cell Culture Evaluation 
Cell culture behavior of the developed two-chamber bioreactor shown in Figure 3.1 was 
evaluated by growing recombinant protein producing cells. The IgG producing CHO cell line 
(CRL-11397, ATCC) was grown in the two-chamber bioreactor. The culture was expanded in T-
flasks up to 400 mL, then it was seeded in the smaller chamber of the bioreactor at a total volume 
of 2.5 L at a seeding density of 3.5×105 viable cells/mL. A BIOSTAT CULTIBAG control unit 
from Sartorius was connected to the optical sensors welded on the walls of each chamber and was 
used to take DO and pH measurements in the culture medium. The sparger inlet filters were 
connected to separate mass flow controllers which were coupled to compressed air, oxygen, and 
carbon dioxide cylinders. The flow rate of different gases into the culture medium was manually 
controlled according to pH and DO values recorded on the BIOSTAT control unit. In 48 hours, 
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the viable cell density was more than doubled reaching 8.0×105 cells/mL in the smaller chamber. 
The culture was transferred to the larger chamber and scaled up to 10 L. The culture was 
monitored for an additional 12 hours. At this point, the cell viability began to decline, and the 
manual control became impractical (cell growth curve is shown in appendix A.7). Further 
validation of the prototype cell culture behavior is required with automated culture control. 
3.6 Conclusions 
The multi-chamber single-use bioreactor presented in this paper is based on a novel 
concept for cell culture in the biopharmaceutical industry. In this study, we presented a two-
chamber bioreactor that allows for cell culture expansion from 1 to 50 L in a single, closed 
system. This volume expansion is 10 times greater than the range currently offered by 
commercially available stirred tank bioreactors. The unique features associated with the 
bioreactor will save upstream equipment cost and space and reduce the risk of microbial 
contamination.  
The two-chamber bioreactor is a simple demonstration of an approach that can be 
extended to more than two chambers. For example, a third chamber with a working volume range 
from 250 to 1,000 L can be integrated into the design presented in this study to form a three-
chamber bioreactor with the capability of a thousand-fold increase of the cell culture volume in a 
single bioreactor. One may expect that such a design will be associated with additional challenges 
in manufacturing, sterilization and operation in terms of complexity and costs. Hence, a risk/cost-
benefit analysis will be needed. 
The early prototype presented in this study operates under conditions that follow general 
recommendations for cell culture bioreactors, and engineering characterization shows that the 
performance of the prototype is comparable to commercially available bioreactors. The purpose 
of this early prototype is to demonstrate proof of a novel approach to cell culture volume 
38 
 
expansion, and in general, the bioreactor is not limited to the configuration used in this study. For 
example, the bioreactor can be modified to accommodate other chamber volumes and geometries, 
as well as other mixing, heating, and sparging mechanisms. The approach to optimizing the 
design of the bioreactor can be simplified by evaluating proposed configurations using CFD 
simulations to predict engineering characteristics, where subsequently only the most promising 
candidates are experimentally validated using cell culture. 
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3.8 Notation 
𝑎  [m-1]  interfacial area of air per unit volume of liquid 
𝐶𝑂2
∗  [kg/m3]  dissolved oxygen saturation concentration in liquid phase 
𝐶𝑂2 [kg/m
3]  dissolved oxygen concentration in liquid phase 
D  [m]  impeller diameter 
H [m]  liquid height 
𝑘𝐿𝑎 [s
-1]  specific oxygen mass transfer coefficient 
𝑛 [s-1]  stirrer rotational speed 
𝑁𝑒  [-]  impeller power number 
P [W]  impeller power input 
Re [-]  Reynolds number 
T [m]  vessel diameter 





ρ  [m/s]  density  






USING CFD SIMULATIONS AND STATISTICAL ANALYSIS TO CORRELATE OXYGEN 
MASS TRANSFER COEFFICIENT TO BOTH GEOMETRICAL PARAMETERS AND 
OPERATING CONDITIONS IN A STIRRED-TANK BIOREACTOR 
 
This Chapter is published online in Biotechnology Progress Journal in February 2019 [112]. 
4.1 Introduction 
The first single-use bioreactor was introduced in the late 1990s as a plastic bag that is 
mixed via wave motion [15]. Since then, single-use bioreactors have gathered a great deal of 
interest and been hugely successful in replacing their stainless-steel counterparts for upstream 
processing in the biopharmaceutical industry [16]. While wave-mixed bioreactors initially 
dominated the single-use technology market, stirred bag systems have gained in popularity and 
are being used in large numbers. The fact that stirred bags are more similar to the stainless-steel 
reusable bioreactors, where there is extensive experience, has facilitated their penetration of the 
market and their integration into modern manufacturing processes [19, 113, 114]. 
Single-use bioreactors are sterilized, ready-to-use, cultivation vessels. They are used once 
and then discarded after the end of the cultivation run. Processes based on single-use technology 
offer many advantages. The use of such disposable systems eliminates the need for cleaning-in- 
place, sterilization-in-place, and cleaning validation. The risk of cross-contamination and  
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production turnaround times are also reduced [90]. Further, single-use bioreactors reduce the 
validation time and shorten time to market [19], which is an enormous advantage given the 
extensive development and increased demand of recombinant protein therapeutics. In 2013, 
estimates indicated that compared to stainless-steel facilities, single-use operated facilities had 
annual production rates that were 27% greater and production costs that were 23% lower on a 
gram of mAb basis [24].  
In addition to the above-mentioned advantages of single-use technology, we have 
proposed a new multi-chamber, single-use bioreactor that possesses additive advantages [115]. 
The proposed design involves chambers of different volumes, where a larger chamber encloses a 
smaller one, all presented as a single closed system that requires only one control unit and support 
structure. Thus, a 50 to 100-fold increase in the culture volume can be achieved in one single bag 
during the seed-train process. That is a substantial enhancement to the current limit of only 5-fold 
increase achievable in any stirred-tank single-use bioreactor on the market. The multi-chamber 
design allows a further reduction in the upstream processing costs. The cost reduction includes 
the cost associated with the purchase, qualification, and maintenance of equipment, as well as the 
cGMP factory footprint occupied by the different seed-train bioreactors and control units. The 
design also reduces the risk of microbial contamination by allowing transfer of the cell culture 
between the different chambers, through internal tubing, via gravity or peristaltic pumps, without 
the need of opening the system. Our early proof of concept work [115] was based on a single-use, 
two-chamber bioreactor design. The smaller chamber had a 3 L maximum operating volume and 
had a geometry similar to the Mobius® CellReady 3 L bioreactor, while the larger chamber had a 
50 L maximum operating volume. The engineering characterization of the two chambers showed 
good agreement with other commercially available bioreactors with the same working volumes. 
However, the 50 L chamber required some design optimizations to improve the oxygen mass 
transfer (kLa) to be more in line with other bioreactors on the market.  
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The aim of the study presented here was to use computational fluid dynamics (CFD) 
simulations to model mixing and gassing in the 50 L chamber of the multi-chamber bioreactor 
and to validate the simulations with the published experimental data. The simulation model was 
then used to study the effect of different impeller and sparger sizes on kLa, as well as the effect of 
using a ring sparger instead of the pipe sparger, which was used in the early 50 L prototype.  
CFD is a powerful tool that has been consistently applied to model stirred-tank 
bioreactors. The CFD models can generate high-resolution localized data regarding some 
parameters that are hard or even impossible to measure, such as the distributions of shear stress 
and turbulent kinetic energy [73]. Many scientific papers have used CFD to model fluid flow and 
turbulence inside agitated systems [46-50]. Other studies used CFD to model multiphase flow 
including gas phase, particle tracking or reaction processes [52, 62-67]. The suitability of CFD 
models for engineering characterization of single-use bioreactors has also been demonstrated. 
Many case studies have been reviewed by Loffelholz et al. [84], as well as some other recent 
studies [85, 86]. These studies involved stirred-tank and wave-mixed bioreactors, as well as other 
bioreactor designs with uncommon mixing mechanisms like the oscillating disk with conical 
orifice in the Vibromix system and the air wheel in the PBS Biotech bioreactor. The case study of 
the PBS bioreactor was unique in the sense that the CFD simulations were used to develop the 
market ready bioreactor based on only a prototype, which relates to one scope of the present 
study regarding the multi-chamber bioreactor development. Applying CFD in the bioreactor 
development process led to a significant reduction in time and costs [84]. CFD has been also used 
to optimize cultivation and scale-up conditions in bioreactors by predicting the critical shear 
stress and hence proposing optimum impeller speeds for cell cultivation processes [87, 88]. 
In the present study, numerical simulations were performed using ANSYS Fluent 17.0 
(ANSYS Inc., Canonsburg, PA). A Eulerian-Eulerian model was employed to model the 
multiphase flow combined with the k-epsilon dispersed turbulence model. A population balance 
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model (PBM) has been previously employed in multiphase simulations of stirred-tank reactors 
[116-118] and was used in this study to predict bubble size distribution in the stirred-tank reactor 
by considering bubble breakage and coalescence. The number and sizes of bins of the PBM for 
different agitation speeds were optimized by trial-and-error approach and were validated by 
experimental data generated from the 50 L chamber of the multi-chamber bioreactor. The model 
was then used to compare between a pipe sparger, which was used in the bioreactor prototype, 
and a ring sparger, in terms of the efficiency of oxygen mass transfer in the bioreactor. Oxygen 
mass transfer coefficient (kLa) is an indication of the oxygen transfer efficiency in the culture 
medium. A higher kLa value is required to ensure that the oxygen demand is met at higher cell 
densities, and to avoid excessive gassing which, in addition to the higher cost, may introduce 
excessive shear on the cells. Generally, while developing a new bioreactor, a design with a high 
(kLa) and a reasonable shear stress will enable growth of higher cell densities, reduce operating 
costs, and eventually result in a bioreactor that more favorably compares to commercially 
available top-tier bioreactors.  
Different sparger and impeller sizes were also examined using the validated CFD model. 
Many studies, as reviewed by Markopoulos et al. [119], have correlated kLa to the operating 
conditions like power input per unit volume (P/V) and superficial gas velocity for a given 
bioreactor geometry. In this study, we present a model equation to correlate kLa in a stirred-tank 
bioreactor to different geometrical and operating factors. The developed model equation 
correlates kLa to geometrical factors (i.e. impeller-to-vessel diameter ratio, D/T, and sparger-to-
impeller diameter ratio, dsp/D), mixing factors (i.e. Reynolds number, Re), and gassing factors 
(i.e. volumetric gas flow per unit liquid volume, Q/VL). The developed model equation can be 
used to help the selection of the proper sparger, impeller, and vessel geometries and dimensions 
to be constructed and integrated during the development process of stirred-tank bioreactors, 
especially the next generation multi-chamber bioreactor prototypes of different operating 
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volumes. The model can also be used to predict the oxygen mass transfer efficiency in stirred-
tank bioreactors under variable operating conditions. 
4.2 Bioreactor Geometry Reconstruction and Mesh Regeneration 
The bioreactor under consideration was the 50 L chamber of the two-chamber, single-use 
bioreactor described earlier (Figure 4.1A) [115]. The chamber was a cylindrical vessel with a 
diameter (T) of 38.0 cm and a height of 67.0 cm. The liquid height at the maximum working 
volume was 42.0 cm which was the height considered in the CFD model. A three-blade impeller 
pitched at 30 degrees was carried on a central, top mounted shaft and was used to mix the fluid 
inside the bioreactor. The impeller diameter (D) was 22.8 cm. The air sparger was placed at the 
bottom center of the bioreactor. The sparger was a pipe with a length of 3.1 cm and constant pore 
sizes (dh) of 10 µm. For CFD simulations, different impeller diameters were examined, as well as 
other pipe spargers of different lengths and ring spargers with variable diameters. Experiments 
and simulations were carried out at impeller tip speeds of 0.6, 1.2 and 1.8 m/s, which for the 
constructed prototype, corresponded to 50, 100 and 150 rpm, respectively. The air sparging rate 
was set at 0.02, 0.05 and 0.10 volume of air per volume of liquid per minute (VVM).  
Booleans for the solid parts of the bioreactor (i.e. shaft, impeller, and sparger) were 
created so that only the fluid domains of the bioreactor were considered for the simulation. Two 
distinct fluid domains were created. A smaller domain, or the moving reference frame (MRF), 
was defined near the impeller and was set as a rotating region with a velocity corresponding to 
the impeller tip speed. The other volume, which was the stationary volume, was the volume away 





Figure 4.1. Illustration of the bioreactor geometry and mesh. 
Unstructured tetrahedral meshes were generated using ANSYS Meshing (ANSYS Inc., 
Canonsburg, PA). Interfaces were defined at the joint boundaries of the two fluid domains 
allowing free flow across the two regions. The ANSYS meshing tool generated unstructured grids 
consisting of tetrahedral elements (Figure 4.1B). Mesh quality has been improved and checked to 
meet the requirement in ANSYS Fluent. Specifically, all mesh elements had skewness less than 
0.83, and 98.4% of the elements had an aspect ratio between 1 and 2. A mesh independence test 
was performed to identify the optimum number of mesh elements that provides accurate results 
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and good computational efficiency. Multiple sets of mesh with different numbers of elements 
were generated, and simulations were run on each of them. The results were initially found to 
vary with the mesh element size until it reached a certain point where the results were constant 
and no longer dependent on the grid size. The kLa value was the parameter selected to perform the 
mesh independence test. As shown in Figure 4.2, increasing the number of mesh elements beyond 
1.48 million cells resulted in negligible differences in kLa values, and thus the 1.48 million grid 
size was selected for all further simulations. For the mesh independence test, simulations were 
run at the bioreactor impeller speed of 150 rpm and an inlet air flow rate of 0.1 VVM. The final 
mesh (shown in Figure 4.1B) contains 1,487,040 elements and 266,038 nodes.  
Figure 4.2. Mesh independence test where kLa is plotted as a function of number of mesh elements. 




4.3 Numerical Setup 
The CFD simulations were carried out using the ANSYS FLUENT 17.0 finite volume 
solver. The bioreactor vessel containing liquid mixed by an impeller and aerated from the bottom 
was represented by a multiphase gas-liquid system. The system was modeled using the Eulerian-
Eulerian multiphase model, where water was the primary continuous phase and air was the 
secondary phase and was dispersed in water as air bubbles.  
All walls were treated with no-slip boundary conditions. The sparger surface was treated 
as air velocity inlet, where the air volume fraction was set to unity. The bioreactor top was set as 
a degassing outlet to allow only air to escape from the bioreactor top boundary and not water. 
Properties of fluids in the simulations were set as follows: for water, 𝜌L = 998.2 kg/m3, μL = 0.001 
kg/m·s, while for air 𝜌G = 1.225 kg/m3, μG = 1.789 × 10-5 kg/m·s, and the water-air interfacial 
tension 𝜎L = 0.072 N/m.  
The phase-coupled SIMPLE algorithm was used for pressure velocity coupling. The 
second order upwind scheme was used for momentum discretization, and the first order upwind 
scheme was used for the turbulent kinetic energy (k) and turbulent dissipation rate (ɛ). QUICK 
scheme was used to solve for volume fraction while the Green-Gauss node-based method was 
used for gradient. For each simulation, single-phase flow was performed first by solving 
continuity and momentum equations. The single-phase solution was then used to initialize the 
multiphase solution. The time step was set to 0.01 s in single-phase simulations and 0.001 s in 
multiphase simulations. The maximum number of iterations per time step was set to 60. 
Convergence was determined by reaching residuals below 1 × 10-5 for all parameters and 1 × 10-4 
for continuity and by reaching a constant kLa value over a significant number of time steps. 
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4.4 Governing Equations  
4.4.1 Eulerian-Eulerian Multiphase Model 
This model involves solving the Navier-Stokes equations assuming constant density and 
viscosity for both phases. The governing equations for mass and momentum conservation are 
𝜕
𝜕𝑡
(𝜌𝑖𝛼𝑖) + ∇ · (𝛼𝑖𝜌𝑖𝑼𝒊) = 0    (Equation 4.1) 
𝜕
𝜕𝑡
(𝜌𝑖𝛼𝑖𝑼𝒊) + ∇ · (𝜌𝑖𝛼𝑖𝑼𝒊𝑼𝒊) = −𝛼𝑖∇𝑝 + ∇ · 𝝉𝐞𝐟 + 𝑹𝒊 + 𝑭𝒊 + 𝛼𝑖𝜌𝑖g  (Equation 4.2) 
where 𝜌𝑖, 𝛼𝑖, and 𝑼𝒊 are the density, volume fraction, and mean velocity vector of phase 𝑖, 
respectively, where the subscript 𝑖 refers to either the liquid (𝐿) or gas (𝐺) phase. The terms 
𝑝, 𝑹𝒊, and 𝑭𝒊 represent the pressure, momentum exchange, and centrifugal forces. The term g is 
acceleration due to gravity. The Reynolds stress tensor, denoted by 𝝉𝐞𝐟, was described by the 𝑘-𝜀 
turbulence model provided by FLUENT and was used with default settings [120]. 
The sum of both liquid and gas phase volume fractions remains unity in every cell 
domain as follows: 
𝛼𝐿 + 𝛼𝐺 = 1    (Equation 4.3) 
The drag force acting on the air bubbles resulting from the relative velocity between the two 
phases is the most important interface force. The drag force for the secondary phase can be 






2 (𝑼𝑮−𝑼𝑳)  (Equation 4.4) 





       (Equation 4.5) 
49 
 
While there are several drag law models provided by FLUENT, Kaiser [122] reported 
that the drag coefficients, 𝐶D, predicted from nine different models were nearly identical at low 
particle Reynolds number, 𝑅𝑒𝑝, and the drag coefficients only began to deviate when 𝑅𝑒𝑝 was 
close to 1,000. In our study, the maximum 𝑅𝑒𝑝 was 0.22, as calculated from Equation 4.7, which 
suggests that any of the drag law models can be used in our simulations with little concern of 
differences. The drag coefficient described by the Schiller and Naumann correlation [121] is 
frequently used in literature to simulate stirred-tank bioreactors [93, 116, 117], and was selected 





    𝑅𝑒𝑝 ≤ 1,000
0.44                        𝑅𝑒𝑝 > 1,000
   (Equation 4.6) 




   (Equation 4.7) 
4.4.2 Turbulence Model 
Because the volume fraction and the density of the secondary phase is low, and the 
density difference between the two phases is high, the dispersed k-ɛ turbulence model was used. 
In this dispersed k-ɛ model, the turbulence of dispersed phase is not considered, and the flow of 
this secondary phase is considered to be laminar [124]. 
The liquid phase turbulence viscosity is described as [125]: 




    (Equation 4.8) 
where the turbulent kinetic energy term for the liquid phase (kLiq) should not be confused with the 
convective mass transfer coefficient (kL) that is a part of the oxygen mass transfer coefficient 
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(kLa). Within Equation 4.8, the transport equations for the turbulent kinetic energy, 𝑘, and the 
turbulent energy dissipation, 𝜀, are given by 
𝜕(𝜌𝐿𝛼𝐿𝑘𝐿𝑖𝑞)
𝜕𝑡
+ ∇ · (𝜌𝐿𝛼𝐿𝑘𝐿𝑖𝑞𝑼𝑳) = ∇ · (𝛼𝐿
𝜇𝑡,𝐿
𝜎𝑘










(𝐶1𝜀𝐺𝑘𝐿 − 𝐶2𝜀𝜌𝐿𝜀𝐿) + 𝛼𝐿𝜌𝐿∏𝜀𝐿 
(Equation 4.10) 
where 𝐺𝑘𝐿 is the rate of production of k, ∏𝑘𝐿 and ∏𝜀𝐿 account for the influence of dispersed 
phase on the continuous phase [126], while 𝐶𝜇, 𝐶1𝜀, 𝐶2𝜀, 𝜎𝑘, and 𝜎𝜀  are model parameters given 
the values 0.09, 1.44, 1.92, 1.0, and 1.3, respectively [120]. 
4.4.3 Population Balance Model 
While constant bubble size models are simple and require less computational time, they 
do not accurately represent the physical system [125, 127]. Bubbles are discharged from the 
sparger with a uniform diameter. Once they are in the medium, however, the bubbles interact with 
the moving primary phase and undergo breakup and coalescence. Bubble breakup occurs when 
the liquid disruptive forces overcome the bubble surface tension, while coalescence happens 
when bubbles collide strongly enough to break the bubble thin film. A population balance model 
provides more accurate information by predicting coalescence and breakup mechanisms and 
providing information on the bubble size and the bubble size distribution within the bioreactor 
[68, 127, 128]. In this study, the method of classes [129, 130] was used for discretizing and 
solving the population balance partial differential equation, which can be written as follows: 
𝜕(𝜌𝐺𝑛𝑖)
𝜕𝑡
+ ∇ · (𝜌𝐺𝑼𝑮,𝒊𝑛𝑖) = 𝜌𝐺(𝐵𝑖𝐶 − 𝐷𝑖𝐶 + 𝐵𝑖𝐵 − 𝐷𝑖𝐵)  (Equation 4.11) 
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In this equation, 𝑛𝑖 is the number of bubbles in the bubble class 𝑖, 𝑈𝐺,𝑖 is the velocity 
vector of gas phase bubbles in the class 𝑖, 𝐵𝑖𝐵 and 𝐵𝑖𝐶  are the bubble birth rates due to breakage 
and coalescence, and 𝐷𝑖𝐵 and 𝐷𝑖𝐶 are the bubble death rates due to breakage and coalescence, 
respectively. These terms are modeled as functions of bubble volumes 𝑉′as follows [129]: 
     𝐵𝑖𝐶 =
1
2
∫ 𝑎(𝑉 − 𝑉′, 𝑉′)𝑛(𝑉 − 𝑉′, 𝑡)𝑛(𝑉′, 𝑡)𝑑𝑉′
𝑉
0
        (Equation 4.12)                             




     (Equation 4.13) 




                  (Equation 4.14) 
 𝐷𝑖𝐵 = 𝑏(𝑉)𝑛(𝑉, 𝑡)                                (Equation 4.15) 
In these equations, 𝑎(𝑉, 𝑉′) is the coalescence rate between the different sized bubbles of 
volumes 𝑉 and 𝑉′, 𝑏(𝑉′) is the breakage rate of bubble with volume 𝑉′, 𝑚(𝑉′) is the number of 
daughter bubbles formed due to fragmentation from bubbles of volume 𝑉′, 𝑛(𝑉, 𝑡) is the number 
of bubbles of volume 𝑉 at time 𝑡, and 𝑝(𝑉, 𝑉′) is the probability density function to determine 
offspring bubbles of volume 𝑉 generated from bubbles of volume 𝑉′.  
Because it is more useful to work in terms of the volume fraction of a particular bin of 
bubbles (fi) than the number of bubbles in that bin (ni), it is convenient to express Equation 3.11 
in different terms. With the volume fraction of bubble size i defined as 
 𝛼𝑖 =  𝑛𝑖𝑉𝑖    (Equation 4.16) 
and fi defined as the ratio of the volume fraction of the i
th bin to the total gas volume fraction, 
        𝑓𝑖 =
𝛼𝑖
𝛼𝐺





∑ 𝑓𝑖 = 1𝑖      (Equation 4.18) 
The population balance equation (Equation 4.11) can be written in terms of 𝑓𝑖 and  𝛼𝐺: 
𝜕(𝜌𝐺𝑓𝑖𝛼𝐺)
𝜕𝑡
+ ∇ · (𝜌𝐺𝑼𝑮,𝒊𝑓𝑖𝛼𝐺) = 𝜌𝐺𝑉𝑖(𝐵𝑖𝐶 − 𝐷𝑖𝐶 + 𝐵𝑖𝐵 − 𝐷𝑖𝐵)  (Equation 4.19) 
Sauter mean diameter (𝑑32) was used as the input bubble diameter in the simulation and was used 





2     (Equation 4.20) 
Many breakage and coalescence models for bubble flow are available. These models, 
however, are quite similar with some minor differences in the model constants or assumptions 
used to develop the model [62]. While the discussion of aggregation and breakage kernels is 
beyond the scope of this paper, it is worth mentioning that several studies [131-134] have detailed 
comparisons between the different breakage and coalescence models, including those proposed 
by Prince and Blanch [135], Luo and Svendsen [136], Luo [137], Chesters [138], Martínez-Bazán 
et al. [139], Alopaeus et al. [140], and Lehr et al. [141]. The findings from these studies suggest 
that there is little difference between the mean flow, gas hold-up and bubble Sauter mean 
diameter predicted by the different models, while there is some difference in the predicted bubble 
size distribution.  
In this study, The FLUENT embedded Luo-Svendsen [136] and Luo [137] models were 
used to model both the breakage and coalescence of bubbles, respectively. The models have been 
frequently used in literature to simulate stirred-tank bioreactors using FLUENT software [116, 
117]. In the breakage model, only turbulent eddies with a scale smaller than the bubble diameter 
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are considered to cause the bubbles to break while larger scale eddies are only considered to 
convect the bubbles. 
4.4.4 Mass Transfer Coefficients and Bubble Diameter 
The models used by Rathore et al. [116] were based on Higbie’s penetration theory [142] 
and were used to theoretically estimate the mass transfer coefficient (𝑘𝐿) and the interfacial area 










    (Equation 4.21) 
         𝑎 =
6𝛼𝐺
𝑑32
     (Equation 4.22) 
where 𝐷𝑂2 is the molecular diffusivity of oxygen and is equal to 1.97 × 10
-9 m2/s [68]. Both 
models were used as user defined functions in FLUENT to predict kLa. 
The original diameter (dp) of the bubbles coming out from the sparger holes of diameter 






   (Equation 4.23) 
The oxygen mass transfer coefficient kLa was experimentally determined by the gassing 
out method as previously described for the 50 L chamber of the multi-chamber single-use 
bioreactor [115]. 
4.5 Statistical Analysis and Correlation Equation 
 A randomized response surface method (RSM) was applied to study the effect on kLa of 
the sparger-to-impeller diameter ratio (dsp/D), impeller-to-vessel diameter ratio (D/T), Reynolds 
number (Re), and the gas flow rate per unit liquid volume (Q/VL). The simulation results used in 
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the analysis were performed at dsp/D ratios: 0.086, 0.173, 0.259, 0.500 and 0.800; D/T ratios: 0.2, 
0.4 and 0.6; Re numbers within the range 20,000 – 100,000; and Q/VL: 1.2, 3.0, and 6.0 liters of 
gas/ liter of liquid/ hour. A total of 16 simulation results at different levels of the four studied 
factors were evaluated by an analysis of variance (ANOVA) statistical test. A quadratic model 
equation was generated to correlate the test factors to kLa values. All data were analyzed using 
Design-Expert software, version 11 (Stat-Ease, Inc., Minneapolis, MN). 
4.6 Results and Discussion 
4.6.1 Single-Phase Flow Pattern 
As shown in Figure 4.3, the velocity contours and vectors show the flow pattern at a mid-
plane of the 50 L bioreactor. The fluid is discharged from the impeller tip toward the vessel wall. 
As the fluid hits the wall, it is divided into two loops that recirculate at the top and the bottom of 
the stirrer. This flow pattern is consistent with what was simulated in the Mobius® CellReady 
bioreactor with a similar 3-blade pitched impeller [86, 93]. Those published flow simulations 
were validated by particle image velocimetry (PIV) [86] and by visual observation of the 
trajectory of small plastic particles suspended in the bioreactor [93].  
 
Figure 4.3. Contours and vector plots of fluid velocity in a single-phase flow at different impeller tip 
speeds. Velocity of liquid (uL) is shown normalized to the tip speed (utip). 
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The highest velocity magnitude was shown at the closest proximity to the impeller tip and 
the velocity gradient migrated away from the tip and across the boundary between moving 
reference frame and the stationary domain, thus reflecting what we know to be representative of 
the physical system. This observation was true for all the three tip speeds tested. The top 
circulation loop showed lower velocities than the lower loop which was also consistent with what 
was previously reported for the Mobius® CellReady bioreactor. 
4.6.2 Multiphase Fluid Simulation and kLa Prediction 
Although assuming a constant bubble diameter throughout the bioreactor operation saves 
computational effort and has been successfully used in some studies [93, 144], our kLa prediction 
from a constant bubble size simulation was substantially different than the experimental results. 
At 0.6 impeller tip speed and 0.1 VVM, the experimental kLa measurement was 7.3 hr-1 while the 
kLa predicted from the constant bubble size simulation was 18.2 hr-1. The PBM simulation, with 
bin sizes displayed in Table 4.1, predicts a more realistic kLa value of 8.0 hr-1.  
4.6.3 Model Validation and Optimization of Bin Sizes 
The agitation speed and aeration rate are expected to affect the bubble size and bubble 
size distribution within the bioreactor, and a single PBM model is incapable of accurately 
predicting the bubble size and size distribution at all of these operating conditions. In our study, 
therefore, the number and sizes of bins were optimized for the different operating conditions 
using a trial-and-error method as has been reported by Sarkar et al. [117] For each impeller tip 
speed, a different number of bins of different bubble diameters were tried, and the PBM model 
was validated by predicting kLa values within 10% deviation from the experimental results at 





Figure 4.4. PBM model validation. (A) validation versus kLa experimental data obtained at different 
impeller tip speeds and a constant aeration rate of 0.1 VVM, (B) validation versus kLa experimental 
data obtained at different aeration rates and a constant impeller tip speed of 1.8 m/s. 
 
The optimized bin number and sizes at different impeller tip speeds are shown in Table 4.1, 
where the original bubble diameter emerging from the sparger predicted from Equation 4.23 was 
always set as the middle bin allowing for equal chances of breakage and coalescence in both 
larger and smaller bins. While the bubble diameter predicted from Equation 4.23 was 0.88 mm, 
the Sauter mean diameter predicted from the PBM simulations was always larger than 0.88 mm, 








Table 4.1. Number and size of bins used in the Population Balance Model to simulate the multiphase 
flow at different impeller tip speeds. 
Tip speed (m/s) 1.8 1.2 0.6 
 Bin bubble diameter (mm) 
Bin-0 7.04 2.66 1.88 
Bin-1 4.98 2.02 1.46 
Bin-2 3.52 1.53 1.13 
Bin-3 2.49 1.16 0.88 
Bin-4 1.76 0.88 0.68 
Bin-5 1.24 0.67 0.53 
Bin-6 0.88 0.50 0.41 
Bin-7 0.62 0.38  
Bin-8 0.44 0.29  
Bin-9 0.31   
Bin-10 0.22   
Bin-11 0.16   
Bin-12 0.11   
 
4.6.4 Effect of Sparger Shape on kLa 
Pipe spargers resulted in approximately 30% lower kLa values than the ring spargers of 
the same surface area, as shown in Figure 4.5A, where simulations were run at an impeller tip 
speed of 1.2 m/s and an aeration rate of 0.1 VVM. A higher gas volume fraction was observed 
with the ring sparger simulations, as shown in Figure 4.5B, which can be attributed to the fact that 




Figure 4.5. Comparison between pipe and ring spargers of same sparging surface area (1X is 
equivalent to the surface area of the sparger used in the prototype). (A) effect of sparger geometry on 
kLa, (B) Effect of sparger geometry on air volume fraction. 
 
The fluid at the impeller tip experiences higher turbulence and better distribution across 
the bioreactor vessel, which can be observed from the top view of the vessel showing dispersed 
gas (Figure 4.6). In agreement with the simulation results, a previous experimental study showed 
similar results [108]. The study showed higher gas hold-up with the ring sparger compared to the 
pipe sparger over a wide range of impeller speeds and gas velocities. Lower impeller speeds 
showed 25% improvement in gas hold-up with the ring sparger and 18% improvement at higher 




Figure 4.6. Top view of the air volume fraction inside the bioreactor with a pipe sparger (left) and a 
ring sparger (right). 
 
4.6.5 Effect of Sparger Size on kLa 
Different sizes of spargers were tested to examine the effect of the sparger size on kLa. 
Simulations were run at a stirrer tip speed of 1.2 m/s and a gassing rate of 0.1 VVM. As shown in 
Figure 4.7A, better kLa values were achieved by increasing the sparger size until some point 
where the use of bigger spargers led to a sharp drop in kLa. The trend of the kLa values with 
increased sparger size was consistent with the trend of the volume fraction of air (Figure 4.7B). 
The best kLa value was achieved when the ratio between the sparger diameter and the impeller 
diameter (dsp/D) was 0.8. At this dsp/D ratio, a 16% increase in the kLa value was observed over 
the smallest sparger size tested, which had a dsp/D ratio of 0.086. A sharp reduction of 43% in kLa 




Figure 4.7. Effect of ring sparger diameter on (A) kLa and (B) air volume fraction. 
 
The air bubble size distribution at a mid-plane of the bioreactor is shown in Figure 4.8, 
where it can be observed that at the small sparger diameter, the air bubbles are purged toward the 
center of the vessel where the fluid velocity and turbulence is low. The bubbles are thus prone to 
coalesce and to escape the vessel quickly from top. In the best case, the sparger diameter to the 
impeller diameter ratio was equal to 0.8, and a fraction of the bubbles is shown to be forced 
towards the impeller tip where the velocity and turbulence are at their maximum, thus causing the 
bubbles to break. The smaller bubbles are thrown toward the vessel wall and residence time of the 
bubbles inside bioreactor is increased. A fraction of the bubbles is also pushed towards the center 
of the vessel, where they coalesce and rise upward. This combination of events allows a better 
distribution of gas inside the vessel, which is reflected in the higher gas volume fraction. In 
contrast, at a sparger diameter that is equivalent to the impeller diameter, the gas bubbles are 
mostly dispersed outward by the impeller and are not efficiently distributed in the center of the 
vessel. That poor distribution of gas bubbles inside the bioreactor leads to a lower gas volume 
fraction and hence a lower kLa. The simulation results are supported by experimental results 
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reported by Rewatkar et al. [108] where a ring sparger of a diameter that is 0.8 of the impeller 
diameter showed a higher gas hold-up over a wide range of impeller speeds compared to other 
ring spargers with a diameter that was either half or equal to the diameter of the impeller. The 
dsp/D ratio of 0.8 was also recommended by McFarlane et al. [145] to enhance gas handling 
capability and energy efficiency in dispersing gas in stirred-tank bioreactors. Birch and Ahmed 
[146] also showed that the gas hold-up dropped significantly when the diameter of the ring 
sparger exceeded the diameter of the impeller. 
 
Figure 4.8. Contour plots of bubble size distribution at dsp/D ratio of 0.09 (left), 0.8 (middle), and 1.0 
(right). 
4.6.6 Effect of Impeller Diameter on kLa 
A number of studies, reviewed by Markpoulos et al. [119], correlated kLa to the power 
input per unit volume (P/V), which was directly proportional to the fifth power of the impeller 
diameter according to the following equation:  
𝑃
𝑉⁄ =
𝑁𝑒 ∙ 𝜌 ∙ 𝑛
3 ∙ 𝐷5
𝑉
     (Equation 3.2) 
In contrast García‐Cortés et al. [147] reported a correlation where kLa was directly 
proportional to the impeller-to-vessel diameter (D/T) ratio raised to the power of 2.8. In the 
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present study, simulations were consistent with the aforementioned findings in the sense that the 
larger impeller diameter produced higher kLa values. For a constant dsp/D ratio of 0.8, the kLa 
value at a 0.6 D/T ratio was higher than at a 0.4 D/T ratio by more than 60% and was more than 
double compared to a D/T ratio of 0.2 (Figure 4.9).  
 
Figure 4.9. Effect of impeller diameter to vessel diameter ratio (D/T) on kLa. 
 
The mid-plane contours of the gas volume fraction (Figure 4.10) show a clear 
enhancement in gas distribution inside the vessel with increasing impeller diameter. The better 
gas distribution can be related to the enhanced mixing behavior, where a larger impeller-to-vessel 




Figure 4.10. Contours of air volume fraction (𝜶𝑮) at the bioreactor midplane with different impeller 
diameters (D/T = 0.2, 0.4, and 0.6). In all cases dsp/D is 0.8, the tip speed is 1.2 m/s, and the aeration 
rate is 0.1 VVM. 
 
4.6.7 Statistical Analysis and Model Equation  
The ANOVA test results were helpful to evaluate the accuracy of the applied model. A 
correlation coefficient (R2) of 0.9650, which was quite close to the adjusted R2 value of 0.9417, 
indicated that the model showed a true relationship between the response and the independent 
variables within the tested range.  
A predicted R2 of 0.8896, with less than 0.2 difference from the adjusted R2 (as suggested 
by the Design-Expert Software), as well as a good fit between simulation results and the model 
predictions, shown in Figure 4.11A, indicated that the model is a good predictor. The small 
standard deviation (0.845) revealed the reproducibility of the model, and the small p-value 
(<0.0001) indicated that the model is highly significant. Contour line maps, shown in Figure 




Figure 4.11. (A) Linear plot of model predicted versus CFD predicted kLa values. (B-G) Contour line 
maps showing the effect of different variables dsp/D, D/T, Re, and gas flow rate on kLa. 
 
The final model equation correlates kLa to the four tested factors within the ranges 
commonly used in cell culture applications and can be written as: 
𝑘𝐿𝑎 = −7.4353 + 0.102752 (𝑅𝑒) − 16.86911 (
𝐷
𝑇
) + 12.6307 (
𝑑𝑠𝑝
𝐷














                      (Equation 4.25) 
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Based on the above model analysis, the response surface model was suitable for 
correlating kLa to both geometrical and operating parameters and thus can be used to predict kLa 
in stirred-tank bioreactors and to optimize the bioreactor geometry and operating conditions.  
4.7 Conclusions 
High efficiency of oxygen mass transfer in a bioreactor is essential for a successful cell 
culture process. Oxygen mass transfer coefficient (kLa) is a widely used parameter to evaluate the 
design and performance of a bioreactor. Over the course of designing a new bioreactor, an 
exceedingly large number of combinations of different geometries and operating conditions may 
be required to be evaluated, which makes the experimental evaluation of all possible 
configurations almost impossible. Thus, CFD is a powerful tool that has been often recruited to 
help design and optimize bioreactor performance, requiring less time and fewer experiments. 
In this study, we presented a CFD model to predict kLa in a stirred-tank bioreactor for 
mammalian cell culture, and the model was validated by experimental kLa measurements. A 
population balance model that accounted for air bubble coalescence and breakup was shown to be 
essential for an accurate prediction of the multiphase flow inside the bioreactor. The validated 
CFD model was used to study the effect on kLa of various sparger geometries and sizes, as well as 
different impeller sizes. A ring sparger was shown to exhibit a superior performance over the pipe 
sparger in terms of kLa and gas hold-up, with an optimum diameter that is 80% of the impeller 
diameter. Reducing the impeller diameter was also shown to decrease kLa inside the stirred-tank 
bioreactor. The CFD model was also used to develop a formula to correlate kLa to sparger size, 
impeller size, and mixing and gassing conditions. While kLa has been a primary factor in 
evaluating stirred-tank bioreactors, existing literature only correlates kLa to the operating 
conditions and a geometry that is assumed to be fixed. While these correlations are useful for 
optimizing an existing bioreactor, they are of limited use when designing a bioreactor with a 
novel geometry. Designing a new bioreactor vessel requires selecting the proper hardware (i.e. 
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impeller or sparger), which negates the assumption of constant geometry and makes the existing 
correlations useless. The original scope of this study was to reduce the effort and time required to 
design and optimize our multi-chamber single-use bioreactor, however, the developed formula 
can also be extended to optimize and predict the performance of other stirred-tank reactors. 
4.8 Notation 
D = Diameter of impeller (m) 
T = Diameter of vessel (m) 
dsp = Diameter of ring sparger (m) 
dh = Diameter of the holes in the sparger (m) 
Q = Gas flow rate (L/s) 
VVM = Volume of air per volume of liquid per minute 
𝜌𝑖 = Density of phase i (kg/m
3), Where i = G (gas) or L (liquid) phase 
μi = Molecular viscosity of phase i (kg/m.s) 
𝜎L = Water-air interfacial tension (N/m) 
k = Turbulent kinetic energy (m2/s2) 
ɛ = Turbulent energy dissipation rate (m2/s3) 
𝛼𝑖= Volume fraction of phase i 
𝑼𝒊 = Velocity vector of phase i (m/s) 
p = Pressure (N/m2) 
𝝉𝐞𝐟 = Stress tensor (N/m
2) 
𝑹𝒊 = Interphase momentum exchange term (N/m
3) 
𝑭𝒊 = Centrifugal forces (N/m
3) 
g = Acceleration due to gravity (m/s2) 
CD = Drag coefficient 
ReP = Reynolds number 
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𝜇𝑡,𝐿 = Liquid phase turbulent viscosity (kg/m.s) 
𝐶𝜇, 𝐶1𝜀, 𝐶2𝜀, 𝜎𝑘, 𝜎𝜀 = Model parameters given the values 0.09, 1.44, 1.92, 1.0, and 1.3, 
respectively 
𝐺𝑘 = The rate of production of turbulent kinetic energy (m
2/s4) 
∏𝑘𝐿, ∏𝜀𝐿= Terms accounting for influence of continuous phase on dispersed phase 
𝑛𝑖 = Number density of bubbles in the i
th bubble class 
𝐵𝑖𝐵 = Birth rate due to breakage (m
-3s-1) 
𝐷𝑖𝐵 = Death rate due to breakage (m
-3s-1) 
𝐵𝑖𝐶  = Birth rate due to coalescence (m
-3s-1) 
𝐷𝑖𝐶 = Death rate due to coalescence (m
-3s-1) 
𝑎(𝑉, 𝑉′) = Coalescence rate prevalent between different sized bubbles of volumes 𝑉 and 𝑉′ (s-1) 
b(𝑉′) = Breakage rate of bubble with volume 𝑉′ (s-1) 
m(𝑉′) = Number of daughter bubbles formed due to fragmentation from bubbles of volume 𝑉′ 
n(𝑉,t) = Number of bubbles of volume V at time t 
p(𝑉, 𝑉′) = Probability density function to determine offspring bubbles of volume V generated 
from bubbles of volume 𝑉′ 
𝑓𝑖 = Ratio of volume fraction of i
th group bubbles and total gas volume fraction 
𝑑32 = Sauter mean diameter of air bubbles 
𝐷𝑂2= Molecular diffusivity of O2 (m
2/s) 
kLa = Volume averaged mass transfer coefficient (s-1) 
a = Interfacial area (m2) 
dP = Bubble diameter (m) 
𝑃 = Impeller power input (W) 
𝑉 = Volume of liquid (m3) 
𝑛 = Stirrer rotational speed (s-1) 
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A multi-chamber single-use bioreactor is an innovative solution to streamline 
biopharmaceutical manufacturing by reducing fixed costs, variable costs, production space, and 
the risk of microbial contamination which can lead to complete loss of product. In this chapter, a 
full commercialization plan is presented. The plan is proposed to be executed by Multivate LLC, 
a limited liability company that licenses the OSU owned technology of the multi-chamber 
bioreactor. 
Like yeast is grown in fermenters to produce alcohol, mammalian cells are grown in 
vessels called bioreactors to produce pharmaceutical drugs. Mammalian cells are the dominant 
platform to produce biopharmaceutical drugs, including recombinant proteins and antibodies. 
Mammalian cell cultures require a tedious, expensive, and risky scale-up process to get to 
production scale volumes. A cell culture starts as just a few milliliters and take weeks to divide 
and grow to reach thousands of liters at the production scale. A traditional single-use bioreactor is 
designed as a single compartment bag with a maximum turndown ratio (i.e., the ratio between the 
maximum and the minimum working volume of the bag) of 5:1. This volume limitation for cell
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cultivation inside a single bioreactor necessitates the use of multiple bioreactors with different 
working volumes throughout the scale-up process. 
 
Figure 5.1. A typical seed-train process with multiple vessels of different volumes, multiple support 
structures, and control units. The marks X indicate intermediate bioreactor steps that could 
potentially be eliminated by using the multi-chamber bioreactor technology. 
Our novel multi-chamber single-use bioreactor allows this entire process to be completed 
in a single container. Thus, by using our bags, biopharmaceutical manufacturers can eliminate 
independent, traditional bioreactor units and can save at least $200,000 in fixed costs. The 
savings can be multiplied by the number of intermediates eliminated. Moreover, the simplified 
process can save customers variable costs of $100,000 each year of bags, as well as up to 
$100,000 annually by reducing labor requirements. Finally, reducing the risk of a contamination 
can potentially prevent lost revenue resulting from the loss of an entire batch of product. The cost 
of bag failure is estimated between $100,000 and $1,000,000 per bag [148]. The proposed 
bioreactor also adds the value of freeing production space for additional upstream processes. So, 
instead of using three pieces of equipment to produce only one batch, our customers can use three 
pieces of Multivate’s equipment and produce three batches, simply allowing for a three-fold 
increase in production volume. 
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Mission: The mission of Multivate is to create an innovative high-quality solution to 
make the biopharmaceutical manufacturing process simpler and more cost effective.  
Vision: The longstanding vision of Multivate is to become the new standard and leading 
single-use bioreactor bag manufacturer in the biopharmaceutical industry. This is through 
providing our customers with the unique solution that will make their mammalian cell culture 
process cheaper, simpler, less risky, and more elegant. 
5.2 Company Overview 
 Multivate, LLC, is an Oklahoma based student startup limited liability company 
launched in November 2017. Multivate’s multi-chamber single-use bioreactor technology is 
invented by the company’s CTO. The technology is patent pending. The full utility patent was 
filed by Oklahoma State University in April 2018. While the company founders are still working 
on developing the technology as a part of their degree requirements, the university is open to 
discuss exclusive options with Multivate’s management team to license the technology at the time 
of their graduation.  
5.2.1 Business Opportunity 
Mammalian cells used in the production of biopharmaceuticals take a long time to divide. 
This makes the upstream processing, starting from a seed vial containing a few milliliters of 




Figure 5.2. A 3D structure and a side view cartoon for a two-chamber bioreactor. (A) heating jacket in 
a tight sealed pocket, (B) internal tubing to aseptically connect optical fibers to optical sensors on the 
smaller chamber. 
A single-use bioreactor system typically consists of a fixed support structure and a 
control unit. The bioreactor is a disposable bag that is inserted in the support structure and 
connected to the control unit which has the process control software installed. The bag is used 
only once and is then disconnected and disposed of when the batch is complete. A traditional 
single-use bag is designed as a single compartment bag with a maximum turndown ratio of 5:1 
for stirred-tank reactors. This volume limitation for cell cultivation inside a single, disposable bag 
necessitates the use of multiple bags with different working volumes throughout the seed-train 
process, which is the process of scaling-up the cell culture until inoculating the production scale 
bioreactor. Each of these intermediate bags typically requires its own control unit and support 
structure. In addition to the high cost, this large amount of equipment requires significant 
production floor space, as well as a regular maintenance, qualification, and documentation upon 
operation. Moreover, a stepwise seed-train process requires connecting separate bags each time 
the cultivated cells and nutrient medium are transferred from the smaller to a larger bag, a 
procedure that requires highly trained personnel working under aseptic conditions.  
The multi-chamber patent pending design, consists of an outer bag, or chamber, 
enclosing one or more additional smaller chambers. Together, all chambers require only a single 





are connected through internal tubing allowing transfer of culture from the smaller chamber to the 
larger one to occur via gravity or peristaltic pumps without the need of opening the system and 
risking microbial contamination.  
5.2.2 The Value Proposition 
By adopting Multivate technology, the multi-chamber single-use bioreactor bag allows 
our customers to complete multiple steps of the seed-train process in a single container. This 
revolutionary solution reduces overall manufacturing costs significantly. At least $200,000 of 
fixed costs associated with the purchase and qualification, in addition to the costs of the cGMP 
footprint of equipment can be saved. The more intermediate equipment to be eliminated, the more 
savings are to be achieved. Our research estimated variable costs savings between $50,000 and 
$100,000 each year of bags purchase, as well as $50,000-100,000 annual savings by reducing 
labor requirements. Moreover, reducing risk of contamination can potentially prevent lost 
revenue resulting from the loss of an entire batch of product. Freeing production space for 
additional seed-trains could also allow for 2-3-fold increase in production volume. 
5.3 Market Analysis 
Multivate considers the market secure, rapidly growing, and accessible for entry.  
5.3.1 Market Trend 
 The single-use bioreactors market is expected to grow from $818 million in 2016 to $2.7 
billion in 2022 at a CAGR of 22% [149]. Our addressable market will be the mammalian cell 
culture bioreactors, which accounts for over 70% of the total bioreactor market share [150]. One 
reason for the rapid market growth over the next few years is that before 2020, $67 billion worth 
biopharmaceuticals will lose patent protection and will be exposed to manufacturing competition 
[151]. This means more companies will compete to manufacture these drugs and to take their 
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share in this huge and fast-growing market. Only in the United States, there are more than 180 
companies that are currently involved with at least one major biosimilar (i.e. generic) in their 
pipeline [152]. The number is expected to increase because of the great opportunity for small 
pharmaceutical companies and start-ups, which will primarily use single-use technology. This is 
because the single-use technology provides decreased capital expenditures and operating costs 
due to the reduction of cleaning, sterilization, and validation steps. In addition, processes based 
on single-use equipment are more flexible, require shorter set-up times, and have significantly 
reduced cross-contamination risk, all of which translates to a faster time to market and more 
robust and reliable production.  
5.3.2 Market Size 
Currently, there are about 500 manufacturing companies worldwide, each may have 
between 1 and 20 manufacturing sites. Assuming only 2 sites per company, and two equipment 
per site, this gives a total market of 2,000 equipment ($300 million total market of equipment), 
and with an average of $135,000 annual purchase of bags per equipment, it is a total market of 
$270 million/year for bags. 
5.3.3 Target Entry Market 
The percentage of biopharmaceutical facilities performing all production in-house 
declined by more than 11% in between 2006 and 2014. The outsourced upstream processes alone 
have more than doubled from 17.1% to 43.2% between 2010 and 2013 [153]. Contract 
manufacturing organizations (CMOs) are more efficient developers of biopharmaceuticals 
because they usually have wider experience with a variety of products and their bioprocessing 
than most product sponsors. Therefore, Multivate has chosen to target CMOs as beachhead 
customers. In the United States alone, we identified at least 100 CMOs that produce 
biopharmaceutical drugs. Multivate has met with some regional CMOs who expressed significant 
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interest. Cytovance Biologics in Oklahoma and Fujifilm Diosynth in Texas expressed willingness 
to have onsite demonstrations and evaluation trials of our product once it is fully developed. 
Another thing we learned from our interviews with industry experts is that at early stages of 
development, companies will tend to perform their own manufacturing trials in an attempt to keep 
control on their process as much as they can before contract manufacturing. This is one reason for 
the growing trend of mobile cleanrooms and fully equipped, modular flexible facilities. This also 
validates our value proposition of the industry need to reduce footprint and fixed costs. As a 
result, our entry market will also target the early stage developers who are trying to develop their 
process before contract manufacturing.  
5.3.4 Market Opportunity Validation 
Multivate management team has conducted over 60 interviews with professionals in the 
industry throughout the business planning process. The team continues to learn more through the 
ongoing interviews as the research continues. Our interviews covered a variety of segments in the 
industry. Customers always mentioned they would like to free more space to add more projects or 
to reduce traffic and personnel/materials flow by including both upstream and downstream 
processing in the same room. Almost all interviewees identified at least one of our value 
propositions as a solution to a current pain. A summary of some key feedbacks gained from our 
interviews is highlighted in Table 5.1. All this information demonstrates that the project has the 







Table 5.1. Key feedback notes on the value propositions from industry professionals  





“Floor space is important. If we can place both the 
upstream and the downstream equipment in the 
same room, it will be a big advantage. We will be 
happy to have your prototype, once ready, for trials 




“If you can really offer this product, sure, I will 




“I have never met a customer who is not interested 






“The culture transfer required as part of the seed-
train process is a substantial pain. It takes a lot of 











5.4.1 Current Competitors 
Current competing technologies are all single compartment reactors with a limited 
turndown ratio. Thus, requiring multiple reactor bags, support structures, and controllers to 
operate a complete upstream production process. The biggest four players in the single-use 
bioreactor market are: Sartorius AG, GE healthcare, Merck Millipore and Thermofisher.  
These companies command most of the market share. These companies are tackling 
current problems like the footprint, high fixed costs, and contamination risk through different 
approaches. For instance, GE and Sartorius developed fully equipped, modular flexible facilities 
to reduce fixed costs and time to market compared to conventional facilities. Their solution, 
however, does not fit customers who already have their facilities established and running, and are 
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only willing to introduce more products. Competitors are also devoting more efforts to 
developing perfusion reactors to save footprint by performing the seed-train process in one 
reactor through a continuous process. Perfusion reactors, however, are significantly more 
complex to operate and will add at least 3-4 days to the process. Reducing contamination risks 
during transfer has been tackled by making sterile connections using external equipment like 
BioWelder/Biosealer from Sartorius. Yet we believe that the industry problems need to be solved 
by reducing the number of equipment used, not by adding more of them. Our patent pending 
design has unique features that offers solutions to all above mentioned problems in a single 
product while still gaining the interest of the broadest spectrum of customers. 
5.4.2 Future Competitors 
Continuous innovation and technological advancements will present new competitors for 
Multivate to stay aware of. Cell-tainer is an example of a small and growing company on the 
market. Cell-tainer® is a wave rocking bioreactor that is currently available in the market with 
the capability of expanding the cell culture volume by approximately 100-fold in the same bag 
(i.e., turndown ratio of ~100:1. However, the unusual mixing principle and restricted scalability 
of a wave-rocking bioreactor often limits its use to low volumes (200 L maximum) and simple 
applications such as seed-train expansion.  The stirred tank reactors are more preferred in 
production scale than the wave-rocking bioreactors due to their higher volume capacity, smaller 
footprint, and conventional mixing mechanism. Another potential competitor is Kuhner Shaker, 
which recently introduced disposable bioreactor systems that are based on orbitally shaking 
mixing mechanism. The new shaking mechanism reduces the cost of bag manufacturing 
significantly, compared to stirred tank reactors, since there is no need to introduce any kind of 
shafts, impellers or gas spargers. Although the mixing technology used by Kuhner Shaker sounds 
interesting, yet it has not proven itself in the market where wave motion and stirred-tank reactors 
still dominates.  
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5.5 Description of Product 
5.5.1 Products Offered and State of Development 
The multi-chamber design consists of an outer bag, or chamber, enclosing one or more 
additional smaller chambers. Together, all chambers require only a single control unit and 
supporting structure that fits the dimensions of the largest chamber.  
 
Figure 5.3. Detailed structure of a two-chamber single-use bioreactor. 
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All chambers are connected through internal tubing. The culture can be transferred from 
one chamber to another through these tubing via gravity or by using peristaltic pumps without the 
need of opening the system and risking microbial contamination. A top-mounted shaft with 
impellers goes from the top of the multi-chamber bag across the base of all smaller chambers 
through an air-tight sealing to serve for mixing in all chambers. 
Multivate offers multi-chamber single-use bioreactor bags that are distributed pre-
sterilized and ready to install and use. A series of two-chamber bags of different volumes will be 
marketed as Multivate 3/50, 10/200 and 50/1,000. As well as a three-chamber Multivate 
5/100/2,000 bag. The numbers in the series name refer to the maximum working volume in each 
chamber, and each chamber typically has a turndown ratio of 5:1. For example, a 10/200 bag has 
a smaller chamber of a maximum working volume of 10 liters and a large chamber of a maximum 
working volume of 200 liters. An operator can start the culture in the smaller chamber at 2 L 
volume and scale it up to 10 L when the cell density reaches the desired value, then the culture 
can be internally transferred to the larger chamber at a volume of 40 L and then finally scaled up 
to 200 L in the larger chamber. Thus, a turndown ratio of 100 (from 2 L to 200 L) can be 
achieved in the Multivate bag. We will also offer control units and support structures to the 
single-use bags. A 200 CU, and a 2,000 CU, to operate and control bags up to 200 L and 2,000 L, 
respectively. The bags and control units will be outsourced for manufacturing.  
5.5.2 Product Development Milestones 
Multivate has working alpha prototypes. The prototypes were tested in terms of mixing 
and gas transfer efficiencies. The prototypes were also proven to grow mammalian cells that 
produce a recombinant IgG antibody. In the first year of operation, Multivate is targeting to 




Table 5.2. Milestones for multi-chamber single-use bioreactor product development 
Product Development Tasks Q1 Q2 Q3 Q4 
Construction of industry 
deployable beta product 
    
Customer trials 
    
Iterations (Design or Process) 
    
Final industry ready product 
    
 
5.5.3 Pricing Strategy 
Based on actual quotes we collected from current vendors, our prices are very 
competitive to the current options on market. Multivate prices the equipment and the bags with 
production, sterilization, testing, packaging costs, and customer value in mind. We also consider 
the price of competitors’ bags and equipment. We price the bioreactor bags between $4,000 and 
$14,000 according to their volume. Our product prices are about 10% less than the average 
market price of the bags of the same volume. For example, the average 1,000 L bag price is 
$8,000 and a 50 L bag price is $3,000, so we are pricing our Multivate 50/1,000 two-chamber bag 
at $10,000 which is about 10% less than the price of the two individual bags sold separately. For 
the equipment, the market price of control units varies between $100,000 and $400,000 according 
to the volume of bags it is used for. We price our equipment at $150,000 with the option of a  
1-month trial before purchase or a 1-year financing option. These options are important to attract 
new customers, taking into consideration that once they purchase the equipment, they will be 
committed to continually purchase our bags. All equipment and bag selling prices have 300% 






Figure 5.4. Products offered and pricing.  
5.6 Operations and Management 
5.6.1 Operations Model 
In our model, our bags are outsourced for manufacturing, sterilization, and testing for 
leakage and integrity at FlexConcepts, a bioprocessing bag manufacturer based in Utah State. We 
have worked with FlexConcepts to design and manufacture our two-camber 3/50 and 10/200 L 
prototypes and to put the design for the other volume models. Equipment will be outsourced for 
manufacturing at PendoTech, a company based in New Jersey. Pendotech proposed a customized 
bioreactor control unit that can fit and operate our unique bag design. Outsourced manufacturing 
will give Multivate the freedom to operate without purchasing large assets within the first few 
years. All Multivate bag series and equipment will be sold directly to our biopharmaceutical 
manufacturing customers. Our engineers will provide customers with on-site training, demos, and 
an ongoing technical support and troubleshooting which is a cornerstone for the continued 
success of our company. The continuous technical support is also important to make sure the 
customers are making the best use of our products. By the end of year 6, we anticipate having 206 
equipment in the field creating over $44 million in total sales and $20 million in net profit. 
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5.6.2 Risks and Contingencies 
Risk 1: From the operations stand point, we could incur a procurement problem if 
FlexConcepts, the manufacturer of our bags, is unable to fulfill orders. While this is 
unforeseeable, Multivate is prepared and already has quotes from other manufacturers. While 
FlexConcepts quote is the lowest, we believe that other offers can be negotiated when it is time to 
go for one of them, thus, to keep our profit margins unaffected. 
Risk 2: One barrier for biopharmaceutical manufacturers against adopting new 
technologies offered by start-ups is the uncertainty that these start-ups can survive, keep up with 
their customers’ demand, and deliver orders on time. For that reason, we will work closely with 
our customers to understand their needs and put an estimated plan for annual consumption. 
Customers who are worried about their order lead time can place orders for their annual needs 
with a quarterly or a half annual delivery plan. 
Risk 3: Most customers require a comprehensive proof that the new bioreactor will work 
perfectly with their projects. This requires generating large amounts data using different cell lines 
that produce different proteins of interest at different culture conditions. While this will be very 
costly and time consuming, it still does not guarantee the generated data will be sufficient to 
convince every customer. Therefore, we believe that the best way is to give our potential 
customers a 1-month demonstration/trial period to test their specific projects on our products.  
5.6.3 Management Team 
5.6.3.1 Chief Officers 
Austin Beaver, a mechanical engineering senior with minor in entrepreneurship, manages 
Multivate business development team as CEO. In 2012, Austin started a residential and 
commercial window cleaning company, which has grown to employ 8 college students and serve 
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over 120 customers in central Oklahoma and north Texas. Through heavy campus involvement, 
leadership positions, and experience in management, Austin has developed communication, 
execution, and leadership skills in addition to his experience with startups and engineering 
knowledge.  
Momen Amer is the inventor of the multi-chamber bioreactor concept. He is currently a 
chemical engineering PhD student. His PhD work is all dedicated to design, develop, and test his 
invention, which is eventually the Multivate’s product. Momen has a bachelor’s degree in 
pharmaceutical sciences and a master’s degree in biotechnology. He spent 5 years working in 
biopharmaceutical companies in both R&D and production facilities, which allowed him to 
develop an extensive experience working with all kinds and scales of single-use bioreactors for 
mammalian cell culture. Momen is acting as the CTO of Multivate.  
Yasmine Gabal, a Chemical Engineering PhD student holding a bachelor’s and a 
master’s degrees in pharmaceutical sciences, is our COO. Yasmine exhibits excellent 
communication skills and a clear understanding of both the business and technical aspects of our 
product, which she uses to actively assist in the logistics and technical sales.  
We are looking to add a sales professional with recorded experience and passion for the 
improvement of the biomanufacturing processes. 
5.6.3.2 Advisory Board 
  Susann Koch has over 25 years of experience in cell culture and biopharmaceutical 
industry. She held managerial positions in top biopharmaceutical companies in 3 continents.  
Josh Ramsey is a chemical engineering professor. He is a co-inventor of Multivate’s 
technology and has been working in the product development during the past 4 years. 
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Richard Gajan has over 15 years in business advising. Richard served as a venture 
advisor for I2E, Inc., a high-profile Oklahoma organization that helps create high technology 
companies. During a period of 5 years, he guided 27 I2E clients in launching businesses that 
collectively raised $13 million in equity funding and $4.5 million in grants.  
5.7 Marketing and Sales Strategy 
5.7.1 Sales Approach 
Multivate adopts a B2B concept with a direct sales approach to sell the Multivate bags 
and equipment to biopharmaceutical manufacturers. We will initially target CMOs and start-up 
self-manufacturers. Our sales personnel will interact with potential customers, develop a 
relationship, and share the unique value propositions we offer. We have already interviewed 
around 60 potential customers and we had interest from nearly all of them in the technology and 
the solution it offers to current problems in industry practices.  
We identified a total of 500 biopharmaceutical manufacturers. The number of 
manufacturing sites for each of company varies widely from 1 up to 20 sites according to the 
company size. Our sales strategy assumes only 2 manufacturing sites per company, and targets 
selling two pieces of equipment to each site. Thus, out of the total 1,000 sites, we have a total 
served market size of 2,000 equipment. In the first year of sales, we will hire one sales person, the 
number will increase to 20 in five years. Each sales person will be responsible for 30 
manufacturing sites, and he is expected to convince 6-10 sites to have an on-site trial for our 
product. Out of these trials we expect 20% closing rate in the first year which will increase up to 
70% in year 5 with gaining more reputation and proving ourselves in the market, and also 
because we expect our existing customers to order their second or third equipment with no need 
for further onsite trials. Every closed sale generates a single equipment purchase of $150,000 and 
a recurring annual bag purchase of $135,000. 
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Because of the high technicality and sometimes the customization of bags required by the 
customers to fit their specific projects, our sales force will always be partnered with a product 
engineer. The salesmen will make initial contact with customers through trade shows, referrals, 
and cold calls. We will follow up with them via emails and phone calls to their production and 
purchasing departments. Once we find a customer that agrees to test our products, the technical 
sales team is responsible for transferring materials and data to and from the customer and to 
arrange for a one- or two-days on-site demonstration and training the customer’s technicians to 
set-up, operate, and control the process with our equipment and bag products. Trial periods of 1 
month will be granted to our potential customers. For the trial, the equipment will be shipped and 
loaned to customer at no charge, while the bags will be sold to the customers at their 
manufacturing costs. The same technical and sales team will be responsible for following up with 
the customers, make sure they are conducting trials on our product and help them with any 
technical problems or concerns. The team will also be responsible to keep contact with the 
customers after the end of the trial period to assess the feedback, offer solutions to whatever 
concerns they have, and close the deal with satisfied customers who want to make the purchase. 
The entire sales process is expected to take approximately nine months from initial contact to first 
sale. Based on our industry knowledge and sales forecasts, one customer account will have a 
single purchase of equipment of $150,000 value, then a recurrent annual purchase of $80,000-
$110,000 for a small volume bags and $140,000-$210,000 for a large volume manufacturing 
account. Once our product is adopted into biopharmaceutical manufacturing, we estimate a total 
of 206 equipment sold and over $44 million in sales by year 6. 
5.7.2 Marketing 
For the industry we plan to enter, demonstrations, equivalency studies, and reputation are 
the most important factors in attracting customers. Our B2B marketing strategy includes scientific 
publications, trade shows, conferences, and on-site trials.  
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Attending and participating in industry trade shows will aim to provide demonstrations to 
engage our customers. This strategy will allow us to interact with high and low volume 
manufacturers. From there, we will develop the next step with interested customers for an on-site 
demo/trial. Our goal is to create ease in finding more information about our product and its 
capabilities through publishing articles and advertisements in trade magazines. We plan to gain 
credibility by having articles of validation and equivalency studies comparing our product to the 
competitor products published in the bioprocessing industry leading magazines like bioprocessing 
international and Biopharm International. BPI and ISPE are very well-attended trade shows 
happening throughout the year to highlight industry innovations and progress. We will use these 
campaigns to feature the values of saving fixed and recurrent costs as well as streamlining the 
process through our innovative bioreactor design. We plan to purchase key words through Google 
ad words, which will allow Multivate to capitalize on Google searches related to single-use 
bioreactors. 
5.8 Investment Opportunity 
Multivate seeks $600,000 in investment and is offering 25% stake of ownership to angel 
investors and funding groups. Our hope is to secure an investor who would accept a position on 
the board of directors and actively help connect the management team with industry professionals 
to help launch Multivate. The ownership and equity structure pre- and post-investment is 







Table 5.3. Cap Table with round 1 of investment 
Owners Percent Ownership 
  On Founding Round 1 
Momen Amer, CTO 50.0% 33.0% 
Austin Beaver, CEO 25.0% 18.0% 
Yasmine Gabal, COO 25.0% 18.0% 
Investor 1 0.0% 25.0% 
Option Pool 0.0% 6.0% 
Total 100.0% 100.0% 
 
5.9 Exit Strategy 
Multivate anticipates being purchased by a large single-use bioreactor manufacturer. In 
the 2017 BioProcess International conference, we already drew the attention of industry big 
players and experts. We were approached by Sartorius and asked to initiate discussions about 
possible collaboration. We were also approached by early investors in Accelerex (the first stirred-
tank single-use bioreactor, now acquired by GE) and we were offered help to find partners or 
licensees for our technology. 
5.10  Financials 
5.10.1 Research Grants and Awards 
Multivate’s technology has raised a total $370,000 of non-dilutive funds since 2015 to 
develop its product. Round 1 of $21,250 was granted to develop and characterize the two-
chamber prototype. Then, a second grant of $25,000 was awarded to evaluate cell culture 
behavior in the prototype. Both grants were awarded by the Technology Development Center at 
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Oklahoma State University. Through Oklahoma Applied Research Support (OARS) program, we 
received $300,000 grant to custom manufacture the control equipment and large volume 
prototypes. Multivate team also secured a $3,000 through NSF I-Corps program which was used 
to conduct customer interviews, and to attend trade shows for marketing, in addition to $18,000 in 
awards from business plan competitions. 
Table 5.4. Sources and use of funds received 
Source Amount Received 
OCAST OARS Research Grant $300,000 
OSU Technology Business Development 
Program 
$21,250  
OSU Technology Business Development 
Program 
$25,000  
Second Place Award 
(LOVE’s Business Plan Competition) 
$10,000 
First Place Award 
(OSU Business Plan Competition) 
$8,000  




5.10.2 Income Statement 
The following income statement is a detailed projection of Multivate’s first 6 years of 
operations upon investment funding. These projections are based on securing several 
biopharmaceutical manufacturers who will buy directly from us and adopt the Multivate 




Table 5.5. Projected income statement 
 
Sales Forecast Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
ASSUMPTIONS:
Number of New Equipment Orders 0 2 10 26 56 112
Total Number of Equipment in Field 0 2 12 38 94 206
Equipment
Control Unit 0 2 10 26 56 112
Bags
3/50L 0 8 48 152 376 824
10/200L 0 8 48 152 376 824
50/1000L 0 8 48 152 376 824
5/100/2000L 0 8 48 152 376 824
Revenue 3,296                            
Grant Funding 300,000$               
 Control Unit -$                       300,000$                 1,500,000$                3,900,000$                     8,400,000$                  16,800,000$               
Total Equipment Sales -$                       300,000$                 1,500,000$               3,900,000$                    8,400,000$                 16,800,000$              
Bags
3/50L -$                       32,000$                    192,000$                    608,000$                        1,504,000$                  3,296,000$                  
10/200L -$                       44,000$                    264,000$                    836,000$                        2,068,000$                  4,532,000$                  
50/1000L -$                       80,000$                    480,000$                    1,520,000$                     3,760,000$                  8,240,000$                  
5/100/2000L -$                       112,000$                 672,000$                    2,128,000$                     5,264,000$                  11,536,000$               
Total Bag Sales -$                       268,000$                 1,608,000$               5,092,000$                    12,596,000$              27,604,000$              
Total Sales 300,000$          568,000$            3,108,000$           8,992,000$               20,996,000$          44,404,000$          
Cost of Goods Sold
Control Unit -$                       75,000$                    375,000$                    975,000$                        2,100,000$                  4,200,000$                  
3/50L -$                       8,000$                      48,000$                      152,000$                        376,000$                     824,000$                     
10/200L -$                       11,000$                    66,000$                      209,000$                        517,000$                     1,133,000$                  
50/1000L -$                       20,000$                    120,000$                    380,000$                        940,000$                     2,060,000$                  
5/100/2000L -$                       28,000$                    168,000$                    532,000$                        1,316,000$                  2,884,000$                  
Cost Of Goods Sold Material -$                       142,000$                 777,000$                    2,248,000$                     5,249,000$                  11,101,000$               
New Customer Bonus -$                       20,000$                    100,000$                    260,000$                        560,000$                     1,120,000$                  
Commission on Bags -$                       8,040$                      48,240$                      152,760$                        377,880$                     828,120$                     
      Royalty Fee OSU (2.5% of Revenue) -$                       14,200$                    77,700$                      224,800$                        524,900$                     1,110,100$                  
Cost Of Goods Sold Total -$                  184,240$            1,002,940$           2,885,560$               6,711,780$            14,159,220$          
Gross Profit On Sales 300,000$          383,760$            2,105,060$           6,106,440$               14,284,220$          30,244,780$          
General and Administrative Expenses 20% 30% 40% 50% 70%
Number of Business Managers 1                             1                                1                                  2                                       3                                   3                                   
Business Manager Salary -$                       75,000$                    75,000$                      170,000$                        300,000$                     300,000$                     
Number of Technical Managers 1                             1$                              1$                                1$                                     2$                                 3$                                 
Technical Manager Salary -$                       75,000$                    75,000$                      85,000$                           200,000$                     300,000$                     
Number of Engineers 1                             1$                              2$                                3$                                     6$                                 10$                               
Engineer Salary -$                       75,000$                    150,000$                    255,000$                        510,000$                     850,000$                     
Number of Salespeople -                         1$                              4$                                8$                                     14$                               20$                               
Sales Salary -$                       50,000$                    200,000$                    400,000$                        700,000$                     1,000,000$                  
Number of Staff -                         1$                              3$                                6$                                     10$                               22$                               
Staff Salary -$                       30,000$                    90,000$                      180,000$                        300,000$                     660,000$                     
Total Personnel 3                             5                               11                               20                                    35                                 58                                 
Taxes and Benefits -$                       82,500$                    150,000$                    273,000$                        513,000$                     735,000$                     
R&D Expenses 250,000$               150,000$                 100,000$                    100,000$                        60,000$                       60,000$                       
Office and Manufacturing Rent Expense -$                       50,000$                    50,000$                      100,000$                        200,000$                     200,000$                     
Marketing 50,000$                 80,000$                    200,000$                    360,000$                        600,000$                     840,000$                     
Equipment for use in demos 37,500$                 75,000$                    300,000$                    600,000$                        1,050,000$                  1,500,000$                  
Travel 10,000$                 25,000$                    100,000$                    200,000$                        350,000$                     500,000$                     
General Counsel & Legal Expense 9,000$                   17,040$                    93,240$                      269,760$                        629,880$                     1,332,120$                  
Insurance 2,000$                   11,360$                    62,160$                      179,840$                        419,920$                     888,080$                     
Depreciation & Amortization 5,400$                      15,800$                      36,067$                           61,333$                       96,600$                       
Office Expenses 8,400$                   10,000$                    22,500$                      45,000$                           90,000$                       90,000$                       
Miscellaneous 9,000$                   11,513$                    63,152$                      183,193$                        428,527$                     907,343$                     
Total SG&A Expenses 375,900$          822,813$            1,746,852$           3,436,860$               6,412,660$            10,259,143$          




Table 5.6. Statement of cash flows  
 
Table 5.7. Balance sheet  
 
  
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Operating Activities
Net Income (loss) (75,900)         (439,053)       358,208        2,669,580     7,871,560       19,985,637    
Charges to net income (loss) not affecting cash
Depreciation 5,400             15,800          36,067           61,333            96,600            
Increase (decrease) in current liabilities
Accounts Receivable (47,333)         (211,667)       (537,667)       (1,212,000)     (2,488,333)     
Accounts Payable 12,530          33,321          125,201        277,917        607,017          1,150,877       
12,530          (14,012)         (86,465)         (259,750)       (604,983)         (1,337,457)     
Net Cash Provided By (Used In) Operating Activities (63,370)        (447,665)      287,543       2,445,897    7,327,910      18,744,780   
Investing Activities
Laptops, cell phones, etc… (6,000)           (6,000)           (4,000)           (4,000)            (4,000)             (4,000)             
Equipment (37,500)         (75,000)         (75,000)         (75,000)         (75,000)           (75,000)           
Demo Equipment (37,500)         (75,000)         (225,000)       (300,000)       (450,000)         (450,000)         
Net Cash Provided By (Used In) Investing Activities (81,000)        (156,000)      (304,000)      (379,000)      (529,000)        (529,000)        
Financing Activities
   Grant Money 300,000        
   Common Stock Sales -                     -                     -                     -                     -                       -                       
Preferred Stock Sales 600,000        -                     -                     -                     -                       -                       
Long Term Loan
Dividend Payments for Tax Liability -                     -                     (107,462)       (800,874)       (2,361,468)     (5,995,691)     
Net Cash Provided By (Used In) Financing Activities 900,000       -                     (107,462)      (800,874)      (2,361,468)    (5,995,691)    
Net Increase (Decrease) In Cash 755,630        (603,665)       (123,920)       1,266,023     4,437,442       12,220,089    
Cash - Beginning of Period -                     755,630        151,965        28,045           1,294,068       5,731,510       
Cash - End of Period 755,630       151,965       28,045          1,294,068    5,731,510      17,951,599   
ASSETS 2018 2019 2020 2021 2022 2023
Current Assets
Cash 755,630          151,965             28,045                  1,294,068            5,731,510               17,951,599            
Total Current Assets 755,630$       151,965$           28,045$                1,294,068$          5,731,510$            17,951,599$          
Fixed Assets
Equipment 37,500            112,500             187,500                262,500                337,500                  412,500                  
Demo Equipment 37,500            112,500             337,500                637,500                1,087,500               1,537,500               
Technology (Laptops, Cellphones...etc) 6,000              12,000               16,000                  20,000                  24,000                    28,000                    
Accumulated Depreciation & Amortization -                       (5,400)                (21,200)                 (57,267)                 (118,600)                 (215,200)                 
     Net Equipment 81,000$          231,600$           519,800$             862,733$             1,330,400$            1,762,800$            
TOTAL ASSETS 836,630$       383,565$          547,845$             2,156,801$         7,061,910$           19,714,399$         
LIABILITIES & SHAREHOLDER EQUITY
Liabilities
Accounts Receivables (47,333)              (259,000)              (796,667)              (2,008,667)             (4,497,000)             
Accounts Payable 12,530            45,851               171,052                448,969                1,055,986               2,206,863               
Loan
Total Liabilities 12,530$         (1,482)$             (87,948)$             (347,698)$           (952,681)$             (2,290,137)$          
Equity
Common Stock Sales -                       -                          -                             -                             -                               -                               
Preferred Stock 600,000          600,000             600,000                600,000                600,000                  600,000                  
retained earnings (75,900)           (514,953)            (264,207)              1,604,499            7,114,591               21,104,537            
Total Shareholder's Equity 524,100$       85,047$             335,793$             2,204,499$          7,714,591$            21,704,537$          
TOTAL LIABILITIES & SHAREHOLDER EQUITY 536,630$       83,565$            247,845$             1,856,801$         6,761,910$           19,414,399$         
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5.10.3 Projections and Assumptions  
- Based on our industry knowledge and sales forecasts, each account will have a single 
purchase of equipment of $150,000 value, then a recurrent annual purchase of approximately 
$135,000 of bags. All Multivate products are sold at 300% markup over the COGS. We 
estimate a total of 206 equipment sold, over $44 million in sales, and $20 million in net profit 
by year 6, and breakeven in year 3. We assume an even number of sales for all our bag and 
equipment sizes.  
- We assume an annual bag purchase for each customer of 16 bags, which represents the 
average number of annual production batches in the industry (3 weeks/batch).  
- During year 1 of operation, efforts will be dedicated to developing, and testing all Multivate 
series bags and equipment. No sales are expected in year 1.  
- In the fifth year of sales, we will have 20 salespersons in total. Salesmen will receive a 
$10,000 bonus upon closing a deal with every new equipment, and a 3% commission on 
annual bag sales. They will also receive an annual base salary of $50,000.  
- Royalties: A royalty fee of 2.5% on revenue will be paid to Oklahoma State University for 
their IP ownership. 
- Management and Operation Staff: In the first three years, Momen will serve as the 
technical manager, Austin as a business manager, and Yasmine as an Operational engineer. 
Starting from year 3 we will start hiring more engineers reaching 10 in year six. 
- Management Salaries: No salaries will be paid to Multivate team in year 1. Momen and 
Yasmine will work full time on Multivate development as part of their PhD thesis work, 
while Austin will be helping in setting up legal documents and partner agreements and he will 
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start working fulltime in year 2. Starting from year 2, the three founders will earn $75,000 
annually that will gradually increase as the company grows.  
- Marketing: We budgeted $5,000 per every on-site trial. Assuming every salesperson makes 
8 onsite trials/year, we budgeted $40,000 for marketing/salesperson + $40,000 annually for 
trade shows and conferences.  
- Depreciation: We assumed a 15-year life span for our bioreactor control units.  
- Taxes and Benefits: We estimated 30% of our employees’ salaries. 
- Equipment for Demos: Control units will be dedicated to sales persons for demos and 
customer trials. We dedicated 2 equipment/salesperson. 
- Travel: Travel assumptions are based on heavy traveling sales force, as well as an 
accompanying engineer for the demos. We budgeted $25,000/salesperson/year 
- Office expense: Initially, office space will be in Riata OSU incubator for startups at 
Stillwater, OK. Lab space will be in the chemical engineering department at OSU since 
Multivate product development is part of our founders PhD thesis work. In year 2 we will 
need to rent a lab space for the R&D work and a small office space that will need to expand 
in year 5. 
- Insurance and legal expenses: We estimate a budget of 2% of COGS for insurance and 3% 
for general counsel and legal expenses  










 Mammalian cell cultures are the dominant platform to produce biopharmaceutical drugs. 
Recombinant mammalian cells are grown in bioreactor vessels under controlled conditions to 
produce the pharmaceutical drug of interest. A high cell density in a large culture volume is 
required to produce a sufficient amount of the pharmaceutical drug of interest to make the 
production process economically efficient. The process of scaling-up mammalian cell culture 
from a few milliliters to thousands of liters at the production scale, however, is expensive, time 
consuming, and labor intensive. 
 In this work, a single-use bioreactor for mammalian cell culture with an innovative 
design was presented. The multi-chamber single-use bioreactor offers several advantages over the 
current solutions available on market. The new bioreactor design offers a reduction in capital 
costs, associated with the purchase and maintenance of multiple pieces of equipment, factory 
footprint, variable costs, and risks of microbial contamination. The first proof-of-concept 
prototype demonstrated comparative engineering characteristics to the commercially available 
bioreactors of similar volume. A convenient method for manufacturing the multi-chamber 
bioreactor with air-tight seals and FDA approved materials was proposed for a second generation, 
customer presentable prototype. 
 The engineering characterization of first prototype led to the identification of some areas 
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for potential improvements in the design. Computational fluid dynamics was recruited to study 
the effect of different hardware configuration on the performance of the bioreactor. Ring spargers 
were shown to be more efficient in terms of oxygen mass transfer than pipe sparges, with an 
optimum diameter that is 0.8 times the diameter of the bioreactor impeller. Larger impellers were 
also shown to be more efficient than smaller ones. The presented work combined both CFD and 
design of experiment approaches to correlate kLa in a stirred-tank reactor to both its geometrical 
parameters and operating conditions. The resulting correlation can be used to predict kLa in a 
bioreactor and to optimize its design, geometry, and operating conditions. All existing literature 
assumed a constant bioreactor geometry while correlating kLa to the bioreactor operating 
conditions. This assumption limited the use of such correlations to optimizing an existing 
bioreactor, while they were not helpful in the process of designing a new bioreactor with a novel 
geometry and selecting the proper hardware. 
To validate the value of the proposed invention, customer discovery interviews were 
conducted to understand the current industry problems and to bridge the gap between lab research 
and industrial needs. The interviews showed a wide acceptance from industry experts to the 
proposed multi-chamber bioreactor as a solution to current pains in the industry practices. A full 
business plan was presented in this work that proved the financial feasibility and economic 
attractiveness of further developing the invention to a market ready product. The extended 
business plan established the basis to developing a profitable business from the proposed 
technology on condition that the required investment is secured. 
Testing the cell culture behavior is the next milestone on the road of developing the 
multi-chamber single-use bioreactor. The extensive engineering characterizations and CFD 
simulations that were carried out in this work are particularly valuable to minimize the risk of 
unsuccessful cell culture processes inside the proposed design. Actual cell culture runs with 
different cell lines and a wide variety of products is yet essential to completely validate the 
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concept. While this process is foreseen to be substantially expensive, establishing the right 
partnerships with biopharmaceutical manufacturers is a key to success. Testing the products of 
potential customers in our prototypes and providing sufficient data to compare the performance of 
our prototypes with the current systems is crucial to build the trust in our product, and it will also 
help to identify the areas for potential improvements in the bioreactor design.  
Delivering a market ready product and accomplishing the full commercialization plan is 
an interdisciplinary effort that requires the cooperation of teams with different backgrounds and 
areas of expertise. Taking advantages of the many technical and financial resources at Oklahoma 
State University is another key for success. The New Product Development Center (NPDC) at 
Oklahoma State University is stocked with expert mechanical and design engineers that would 
provide a great help to establish an in-house bag manufacturing process for multi-chamber 
bioreactors to cover the whole production scale spectrum. Cowboy Technologies is a source of 
capital investment that aims to identify and work with the university generated technologies 
which have a promising commercialization potential. Working closely with Cowboy 
Technologies will provide a good opportunity to secure funds required to develop and test the 
next generation prototypes and to provide the project with the industry leads needed to establish 
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A.1. Technical drawing of the two chambers of the 50 L bioreactor prototype 
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